Egfr - epidermal growth factor receptor Gene
Also Known as Wa5; wa2; Erbb; Errp; wa-2; Errb1; 9030024J15Rik
Species: Mus musculus
About Egfr
This gene has 5 transcripts (splice variants), 283 orthologues, 53 paralogues and is associated with 180 phenotypes. Broad expression in liver adult (RPKM 26.7), liver E18 (RPKM 8.7) and 15 other tissues.
Summary
Enables epidermal growth factor binding activity and epidermal growth factor-activated receptor activity. Involved in cellular response to amino acid stimulus and positive regulation of fibroblast proliferation. Acts upstream of or within several processes, including animal organ development; epidermal growth factor receptor signaling pathway; and protein autophosphorylation. Located in several cellular components, including basolateral plasma membrane; endocytic vesicle; and perinuclear region of cytoplasm. Is expressed in several structures, including alimentary system; brain; integumental system; limb; and respiratory system. Used to study Coronavirus infectious disease and aortic valve disease. Human ortholog(s) of this gene implicated in several diseases, including colorectal cancer; lung non-small cell carcinoma (multiple); pancreatic cancer; prostate cancer; and pulmonary Tuberculosis. Orthologous to human EGFR (epidermal growth factor receptor). [provided by Alliance of Genome Resources, Apr 2022]
Egfr Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_207655.2 | NP_997538.1 | epidermal growth factor receptor isoform 1 precursor |
| NM_007912.4 | NP_031938.1 | epidermal growth factor receptor isoform 2 precursor |
Gene Ontology
- Molecular Function
- Biological Process
- Cellular Component
| Cellular Component GO Annotation | Evidence | Verweise | Source |
|---|---|---|---|
| located in basolateral plasma membrane |
IDA
IDA: Inferred from direct assay
|
7723235 | MGI |
| located in cell surface |
IDA
IDA: Inferred from direct assay
|
23918928 | MGI |
| located in endocytic vesicle |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in intracellular anatomical structure |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in nucleus |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| located in perinuclear region of cytoplasm |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| is active in plasma membrane |
IDA
IDA: Inferred from direct assay
|
6248866 | MGI |
| located in plasma membrane |
IDA
IDA: Inferred from direct assay
|
7641815 | MGI |
| is active in plasma membrane |
IGI
IGI: Inferred from genetic interaction
|
28783046 | MGI |
Egfr Protein Structure
Recep_L_domain: pfam01030 (56 - 167)
Furin-like: pfam00757 (183 - 334)
Recep_L_domain: pfam01030 (361 - 480)
GF_recep_IV: pfam14843 (504 - 635)
TM_ErbB1: cd12093 (633 - 678)
PTKc_EGFR: cd05108 (705 - 1017)
- 0
- 200
- 400
- 600
- 800
- 1000
- 1210 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
epidermal growth factor receptor |
|
Recombinant Egfr Proteins
| Art. -Nr. | Produktname | Accession | Reinheit |
|---|---|---|---|
| HY-P72988 | EGFR Protein, Mouse (HEK293, Fc) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P72989 | EGFR Protein, Mouse (HEK293, His, solution) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Rare Diseases
|
|---|---|---|---|---|
| HY-15772 | Osimertinib | Inhibitor | 99.96% | Yes |
| HY-P9907 | Trastuzumab | Inhibitor | 99.80% | Unkown |
| HY-P9905 | Cetuximab | Inhibitor | 99.81% | Unkown |
| HY-50895 | Gefitinib | Inhibitor | 99.99% | Yes |
| HY-138298A | Trastuzumab deruxtecan | Inhibitor | 99.89% | Unkown |
| HY-50896 | Erlotinib | Inhibitor | 99.99% | Yes |
| HY-10261 | Afatinib | Inhibitor | 99.92% | Yes |
| HY-138298 | Trastuzumab deruxtecan (solution) | Inhibitor | 99.40% | Unkown |
| HY-50898 | Lapatinib | Inhibitor | 99.83% | Yes |
| HY-16069 | Tucatinib | Inhibitor | 99.82% | Yes |
| HY-P9921 | Trastuzumab emtansine | Inhibitor | 99.74% | Unkown |
| HY-32721 | Neratinib | Inhibitor | 99.94% | Yes |
| HY-P9985 | Disitamab vedotin | Inhibitor | 99.06% | Unkown |
| HY-13272 | Dacomitinib | Inhibitor | 99.74% | Yes |
| HY-15772A | Osimertinib mesylate | Inhibitor | 99.97% | Yes |
| HY-109061 | Lazertinib | Inhibitor | 99.87% | Unkown |
| HY-P9921A | Trastuzumab emtansine (solution) | 98.27% | Unkown | |
| HY-12008 | Erlotinib Hydrochloride | Inhibitor | 99.94% | Yes |
| HY-10261A | Afatinib dimaleate | Inhibitor | 99.74% | Yes |
| HY-112870 | Firmonertinib | Inhibitor | 99.89% | Unkown |
| HY-112823 | Almonertinib | Inhibitor | 99.83% | Unkown |
| HY-104065 | Pyrotinib | Inhibitor | 99.89% | Unkown |
| HY-50895A | Gefitinib hydrochloride | Inhibitor | 99.85% | Yes |
| HY-132842 | Sunvozertinib | Inhibitor | 99.62% | Unkown |
| HY-N0281 | Daphnetin | Inhibitor | 99.77% | Unkown |
| HY-135815 | Mobocertinib | Inhibitor | 99.60% | Yes |
| HY-15164A | Icotinib | Inhibitor | 99.96% | Yes |
| HY-79077 | Osimertinib dimesylate | Inhibitor | 99.96% | Yes |
| HY-32721B | Neratinib maleate | Inhibitor | 99.74% | Yes |
| HY-164718 | Sevabertinib | Inhibitor | 99.90% | Unkown |
| HY-50898A | Lapatinib ditosylate | Inhibitor | 99.96% | Yes |
| HY-19730 | Olmutinib | Inhibitor | 99.88% | Unkown |
| HY-112870A | Firmonertinib mesylate | Inhibitor | 99.97% | Unkown |
| HY-15772R | Osimertinib (Standard) | Inhibitor | 99.69% | Unkown |
| HY-50898B | Lapatinib ditosylate monohydrate | Inhibitor | 99.99% | Yes |
| HY-104065B | Pyrotinib dimaleate | Inhibitor | 98.04% | Unkown |
| HY-112823B | Almonertinib hydrochloride | Inhibitor | 98.92% | Unkown |
| HY-112823A | Almonertinib mesylate | Inhibitor | 99.67% | Unkown |
| HY-135815A | Mobocertinib succinate | Inhibitor | 99.83% | Yes |
| HY-50896R | Erlotinib (Standard) | Inhibitor | 99.97% | Unkown |
| HY-16069A | Tucatinib hemiethanolate | Inhibitor | 98.82% | Yes |
| HY-15164 | Icotinib Hydrochloride | Inhibitor | 99.89% | Yes |
| HY-50895R | Gefitinib (Standard) | Inhibitor | 99.94% | Unkown |
| HY-118263 | Dacomitinib hydrate | Inhibitor | 99.54% | Unkown |
| HY-12008R | Erlotinib Hydrochloride (Standard) | Inhibitor | 99.73% | Unkown |
| HY-135815B | Mobocertinib mesylate | Inhibitor | / | Unkown |
| HY-10261D | Afatinib oxalate | Inhibitor | / | Unkown |
| HY-50898C | Lapatinib tosylate | Inhibitor | / | Unkown |
| HY-50895B | Gefitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-101820A | Simotinib hydrochloride | Inhibitor | / | Unkown |
| HY-12008A | Erlotinib mesylate | Inhibitor | / | Unkown |
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9977 | Amivantamab | Inhibitor | 99.90% | Unkown |
| HY-P9912 | Pertuzumab | Inhibitor | 99.80% | Unkown |
| HY-P99041 | Panitumumab | Inhibitor | 99.77% | Unkown |
| HY-P99380 | Zanidatamab | Inhibitor | 98.56% | Unkown |
| HY-P99507 | Zenocutuzumab | Inhibitor | 99.9% | Unkown |
| HY-P9968 | Nimotuzumab | Inhibitor | 96.80% | Unkown |
| HY-P9964 | Necitumumab | Inhibitor | 99.82% | Unkown |
| HY-P99030 | Margetuximab | Inhibitor | ≥99.0% | Unkown |
Clinical Phase
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Phase |
|---|---|---|---|---|
| HY-14596 | Genistein | Inhibitor | 99.82% | Phase 4 |
| HY-137433 | Befotertinib | Inhibitor | 99.77% | Phase 4 |
| HY-131686 | Ganglioside GT1b (bovine) ammonium | Activator | 98.0% | Phase 4 |
| HY-50895G | Gefitinib (GMP) | Inhibitor | / | Phase 4 |
| HY-P99813 | Patritumab deruxtecan | 99.08% | Phase 3 | |
| HY-164702 | BL-B01D1 | Inhibitor | 98.40% | Phase 3 |
| HY-18750 | Zorifertinib | Inhibitor | 99.37% | Phase 3 |
| HY-171265 | Becotatug vedotin | Degrader | 96.99% | Phase 3 |
| HY-15729 | Rociletinib | Inhibitor | 99.67% | Phase 3 |
| HY-15730 | Poziotinib | Inhibitor | 99.96% | Phase 3 |
| HY-132259 | Depatuxizumab mafodotin | 99.65% | Phase 3 | |
| HY-12872 | Nazartinib | Inhibitor | 99.53% | Phase 3 |
| HY-164762 | Trastuzumab rezetecan | Inhibitor | 98.01% | Phase 3 |
| HY-112299 | Zipalertinib | Inhibitor | 99.62% | Phase 3 |
| HY-139920 | Oritinib | Inhibitor | 99.59% | Phase 3 |
| HY-19803 | Naquotinib mesylate | Inhibitor | 98.06% | Phase 3 |
| HY-19816A | Avitinib maleate | Inhibitor | 99.86% | Phase 3 |
| HY-13314 | Tesevatinib | Inhibitor | 99.41% | Phase 3 |
| HY-120590 | Ruserontinib | Inhibitor | 99.32% | Phase 3 |
| HY-P990697 | Anvatabart | Inhibitor | 98.15% | Phase 3 |
| HY-138751A | limertinib diTFA | Inhibitor | 98.96% | Phase 3 |
| HY-118998 | TX2-121-1 | Degrader | / | Phase 3 |
| HY-10530A | Varlitinib tosylate | Inhibitor | / | Phase 3 |
| HY-109189A | Rezivertinib hydrochloride | Inhibitor | / | Phase 3 |
| HY-N14349 | Asterriquinone | Inhibitor | / | Phase 3 |
| HY-106204 | Nelipepimut-S | / | Phase 3 | |
| HY-172820 | Trastuzumab envedotin | Inhibitor | / | Phase 3 |
| HY-13050 | Sapitinib | Inhibitor | 99.93% | Phase 2 |
| HY-10367 | Canertinib | Inhibitor | 99.74% | Phase 2 |
| HY-32718 | Pelitinib | Inhibitor | 99.13% | Phase 2 |
| HY-153268 | Silevertinib | Inhibitor | 99.74% | Phase 2 |
| HY-10045 | AEE788 | Inhibitor | 98.39% | Phase 2 |
| HY-14674 | CP-724714 | Inhibitor | 98.72% | Phase 2 |
| HY-10333 | BMS-690514 | Inhibitor | 99.68% | Phase 2 |
| HY-19985 | PF-06459988 | Inhibitor | 99.10% | Phase 2 |
| HY-12972 | Mavelertinib | Inhibitor | 99.34% | Phase 2 |
| HY-172429A | Enozertinib hemihydrate | Inhibitor | 99.98% | Phase 2 |
| HY-17632 | Tarloxotinib bromide | Inhibitor | 98.75% | Phase 2 |
| HY-19815 | Olafertinib | Inhibitor | 99.51% | Phase 2 |
| HY-10251 | BMS-599626 | Inhibitor | 98.56% | Phase 2 |
| HY-107367A | Epertinib hydrochloride | Inhibitor | 98.15% | Phase 2 |
| HY-155537 | Pruvonertinib | Inhibitor | 99.50% | Phase 2 |
| HY-19909 | NRC-2694 | Antagonist | 99.84% | Phase 2 |
| HY-153974 | BBT-176 | Inhibitor | 98.98% | Phase 2 |
| HY-W423595 | BEBT-109 | Inhibitor | 98.72% | Phase 2 |
| HY-107367 | Epertinib | Inhibitor | ≥98.0% | Phase 2 |
| HY-177414 | BB-1701 | Inhibitor | 98.81% | Phase 2 |
| HY-101756 | SDZ281-977 | 98.00% | Phase 2 | |
| HY-164387A | Sutetinib maleate | Inhibitor | / | Phase 2 |
| HY-10223 | CUDC-101 | Inhibitor | 99.05% | Phase 1 |
| HY-13501 | Mubritinib | Inhibitor | 99.91% | Phase 1 |
| HY-164202 | ORM-5029 | Inhibitor | 96.53% | Phase 1 |
| HY-18957 | Lifirafenib | Inhibitor | 98.01% | Phase 1 |
| HY-144680 | BLU-945 | Inhibitor | 99.61% | Phase 1 |
| HY-14346 | PD153035 | Inhibitor | 98.56% | Phase 1 |
| HY-171124 | Tilatamig samrotecan | Inhibitor | 95.26% | Phase 1 |
| HY-136789 | Tuxobertinib | Inhibitor | 99.88% | Phase 1 |
| HY-15196 | TAK-285 | Inhibitor | 98.99% | Phase 1 |
| HY-103443 | HKI-357 | Inhibitor | 99.24% | Phase 1 |
| HY-B0794 | AZ7550 | Inhibitor | 97.09% | Phase 1 |
| HY-116437 | Selatinib | Inhibitor | 98.56% | Phase 1 |
| HY-155079 | DZD1516 | Inhibitor | 99.62% | Phase 1 |
| HY-101820 | Simotinib | Inhibitor | 99.39% | Phase 1 |
| HY-10346 | AV-412 | Inhibitor | 99.17% | Phase 1 |
| HY-153110 | Larotinib | Inhibitor | 99.50% | Phase 1 |
| HY-139300 | Epitinib | Inhibitor | 99.95% | Phase 1 |
| HY-164694 | Emupertinib | Inhibitor | 99.10% | Phase 1 |
| HY-171747 | AMT-562 | Antagonist | 98.65% | Phase 1 |
| HY-177895 | IAM1363 | Inhibitor | 99.40% | Phase 1 |
| HY-111553 | TAS0728 | Inhibitor | 99.71% | Phase 1 |
| HY-128778 | Gozanertinib | Inhibitor | 98.37% | Phase 1 |
| HY-164307 | Pebezertinib | Inhibitor | 99.56% | Phase 1 |
| HY-164464 | BPI-15086 | Inhibitor | / | Phase 1 |
| HY-15732 | BGB-102 | Inhibitor | 99.52% | Phase 1 |
| HY-104066A | Theliatinib tartrate | / | Phase 1 | |
| HY-181954 | ZW-49 | Inhibitor | / | Phase 1 |
| HY-153856 | TAS2940 | Inhibitor | / | Phase 1 |
| HY-177710 | MEDI4276 | / | Phase 1 | |
| HY-110039 | BIBX 1382 dihydrochloride | Inhibitor | / | Phase 1 |
| HY-110333 | BMS-599626 dihydrochloride | Inhibitor | / | Phase 1 |
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Phase |
|---|---|---|---|---|
| HY-P99041A | Panitumumab (anti-EGFR) | Inhibitor | 99.02% | Phase 4 |
| HY-P99969 | Inetetamab | Inhibitor | 96.54% | Phase 4 |
| HY-P99854A | Disitamab (powder) | Inhibitor | 98.44% | Phase 4 |
| HY-P99041B | Panitumumab (powder) | Inhibitor | / | Phase 4 |
| HY-P99275 | Patritumab | Inhibitor | 99.28% | Phase 3 |
| HY-P99406 | Petosemtamab | Degrader | 99.90% | Phase 3 |
| HY-P99676 | Izalontamab | Inhibitor | 99.89% | Phase 3 |
| HY-P99849 | Depatuxizumab | Inhibitor | 99.58% | Phase 3 |
| HY-P99155 | Zalutumumab | 98.34% | Phase 3 | |
| HY-P990049 | Becotatug | Inhibitor | 99.00% | Phase 3 |
| HY-P99437 | Anbenitamab | Inhibitor | 99.22% | Phase 3 |
| HY-P99455 | Bafisontamab | Inhibitor | 99.9% | Phase 3 |
| HY-P99630 | Gancotamab antibody | Inhibitor | ≥99.0% | Phase 3 |
| HY-P99831 | Coprelotamab | / | Phase 3 | |
| HY-P991588 | HLX-22 | Antagonist | 99.47% | Phase 3 |
| HY-P991508 | Sym004 | Inhibitor | 98.97% | Phase 3 |
| HY-P99155A | Zalutumumab (powder) | Inhibitor | / | Phase 3 |
| HY-P99268 | Seribantumab | Inhibitor | 96.043% | Phase 2 |
| HY-P9969 | Matuzumab | 98.07% | Phase 2 | |
| HY-P99936 | Elgemtumab | Inhibitor | 99.00% | Phase 2 |
| HY-P99778 | Ontuxizumab | 99.85% | Phase 2 | |
| HY-P990314 | AFM24 | Inhibitor | 96.26% | Phase 2 |
| HY-P99295 | Imgatuzumab | Inhibitor | 99.41% | Phase 2 |
| HY-P990071 | Fepixnebart | Inhibitor | 96.46% | Phase 2 |
| HY-P99605 | Cinrebafusp alfa | Inhibitor | 98.53% | Phase 2 |
| HY-P99306 | Modotuximab | Inhibitor | 99.08% | Phase 2 |
| HY-P99628 | Futuximab | Inhibitor | 98.09% | Phase 2 |
| HY-P991237 | Nezutatug | Inhibitor | 99.9% | Phase 2 |
| HY-P991571 | GC1118 | 99.22% | Phase 2 | |
| HY-P990913 | Dalmitamig | 97.158% | Phase 2 | |
| HY-P99672 | Istiratumab | Inhibitor | 98.45% | Phase 2 |
| HY-P991238 | MEDI4276 Antibody | Inhibitor | 96.5212% | Phase 2 |
| HY-P9994 | Pertuzumab zuvotolimod | Inhibitor | 98.64% | Phase 2 |
| HY-P991507 | SCT200 | Inhibitor | 99.09% | Phase 2 |
| HY-P991092 | IBI-334 | Inhibitor | 98.18% | Phase 2 |
| HY-P991240 | CDX-3379 | Inhibitor | 99.38% | Phase 2 |
| HY-P991572 | MM-151 | Antagonist | / | Phase 2 |
| HY-P991524 | MM-111 | Inhibitor | / | Phase 2 |
| HY-P99500 | Cetuximab sarotalocan | Inhibitor | / | Phase 2 |
| HY-P991233 | BAT1006 | Inhibitor | / | Phase 2 |
| HY-P99896 | Runimotamab | 99.00% | Phase 1 | |
| HY-P99386 | Vesencumab | Inhibitor | 99.34% | Phase 1 |
| HY-P99304 | Lumretuzumab | Inhibitor | ≥99.0% | Phase 1 |
| HY-P99685 | Laprituximab emtansine | Inhibitor | 97.66% | Phase 1 |
| HY-P991235 | FS102 | Degrader | / | Phase 1 |
| HY-P991244 | REGN-1400 | Inhibitor | / | Phase 1 |
| HY-P991984 | SIBP-03 | Inhibitor | / | Phase 1 |
| HY-P990609 | KHK-2866 | 98.23% | Phase 1 |
Pre-clinical Phase
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Rare Diseases
|
|---|---|---|---|---|
| HY-12000 | AG490 | Inhibitor | 99.86% | Unkown |
| HY-P0221 | PACAP (1-38), human, ovine, rat | Inducer | 99.99% | Unkown |
| HY-13524 | AG-1478 | Inhibitor | 99.57% | Unkown |
| HY-P10408 | Candidalysin | Activator | 99.81% | Unkown |
| HY-101084 | NSC 228155 | Activator | 99.58% | Unkown |
| HY-164992 | Trastuzumab vedotin | Inhibitor | 98.05% | Unkown |
| HY-13595 | Chrysophanol | Inhibitor | 99.73% | Unkown |
| HY-N0280 | Corosolic acid | 99.95% | Unkown | |
| HY-16558 | Butein | Inhibitor | 99.64% | Unkown |
| HY-N2409 | Delphinidin chloride | Inhibitor | 98.0% | Unkown |
| HY-171135 | Cetuximab MMAE | Inhibitor | 99.64% | Unkown |
| HY-100848 | TX1-85-1 | Inhibitor | 99.65% | Unkown |
| HY-12461 | WS6 | Activator | 99.30% | Unkown |
| HY-100958 | 4-DAMP | Inhibitor | 99.96% | Unkown |
| HY-B0793 | AZ-5104 | Inhibitor | 99.91% | Unkown |
| HY-156698 | HJM-561 | Degrader | 99.52% | Unkown |
| HY-N7922 | Urolithin M5 | 97.31% | Unkown | |
| HY-100742 | GNE-140 racemate | Inhibitor | 99.25% | Unkown |
| HY-19816 | Avitinib | Inhibitor | 99.95% | Unkown |
| HY-123921 | Gefitinib-based PROTAC 3 | Degrader | 99.98% | Unkown |
| HY-15644 | Tyrphostin 23 | Inhibitor | 98.19% | Unkown |
| HY-14596R | Genistein (Standard) | Inhibitor | 98.70% | Unkown |
| HY-168438 | ERBB agonist-1 | Agonist | 99.16% | Unkown |
| HY-108052 | Delphinidin 3-glucoside chloride | Inhibitor | 99.89% | Unkown |
| HY-N0447 | 8-Gingerol | Inhibitor | 99.82% | Unkown |
| HY-162713 | MTX-531 | Inhibitor | 99.87% | Unkown |
| HY-120852 | JG26 | Inhibitor | 98.14% | Unkown |
| HY-112411 | PD 174265 | Inhibitor | 98.35% | Unkown |
| HY-W016412 | Coenzyme Q0 | Inhibitor | 99.79% | Unkown |
| HY-129550 | BI-4020 | Inhibitor | 99.30% | Unkown |
| HY-13896 | PD168393 | Inhibitor | 98.01% | Unkown |
| HY-41404 | Piperonylic acid | 99.94% | Unkown | |
| HY-109189 | Rezivertinib | Inhibitor | 99.62% | Unkown |
| HY-100434 | PD-161570 | Inhibitor | 98.78% | Unkown |
| HY-48999A | FSK hydrochloride | 99.97% | Unkown | |
| HY-131864 | SJF-1528 | Degrader | 98.90% | Unkown |
| HY-141640 | MS154 | Inhibitor | 99.71% | Unkown |
| HY-138751 | limertinib | Inhibitor | 99.15% | Unkown |
| HY-N0211 | Cyasterone | Inhibitor | 99.58% | Unkown |
| HY-N2450 | Sulforaphene | Inhibitor | 99.78% | Unkown |
| HY-18609 | PD158780 | Inhibitor | 99.47% | Unkown |
| HY-155736 | MAPK-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-W782083 | p-SCN-Bn-NOTA trihydrochloride | 99.75% | Unkown | |
| HY-125168 | EGA | Modulator | 99.76% | Unkown |
| HY-14596S | Genistein-d4 | Inhibitor | 98.81% | Unkown |
| HY-N2184 | Furanodienone | 99.90% | Unkown | |
| HY-10530 | Varlitinib | Inhibitor | 99.92% | Yes |
| HY-141676 | HyT36 | Degrader | 96.0% | Unkown |
| HY-N7005 | Clitorin | Inhibitor | 99.45% | Unkown |
| HY-15375 | Allitinib | Inhibitor | 98.88% | Unkown |
| HY-100213 | EAI045 | Inhibitor | 99.06% | Unkown |
| HY-10322 | Falnidamol | Inhibitor | 99.41% | Unkown |
| HY-N0891 | Tubeimoside II | Inhibitor | 99.90% | Unkown |
| HY-138916 | PF-06672131 | Inhibitor | 99.47% | Unkown |
| HY-10367A | Canertinib dihydrochloride | Inhibitor | 99.68% | Unkown |
| HY-157229 | STX-721 | Inhibitor | 98.25% | Unkown |
| HY-115605 | CN009543V | Agonist | 99.37% | Unkown |
| HY-20878 | Tyrphostin AG 879 | Inhibitor | 99.26% | Unkown |
| HY-156712 | Depatuxizumab MMAE | Inhibitor | 99.73% | Unkown |
| HY-N9330 | Broussoflavonol F | Inhibitor | 98.11% | Unkown |
| HY-18963 | Lavendustin A | Inhibitor | 98.95% | Unkown |
| HY-B0794B | AZ7550 Mesylate | Inhibitor | 98.70% | Unkown |
| HY-10261B | (E/Z)-Afatinib | Inhibitor | 99.98% | Unkown |
| HY-131865 | SJF-1521 | Degrader | 99.65% | Unkown |
| HY-124813 | PDZ1i | Inhibitor | 99.29% | Unkown |
| HY-161536 | PROTAC EGFR degrader 9 | Inhibitor | 98.35% | Unkown |
| HY-N2510 | Myristicin | Inhibitor | 99.89% | Unkown |
| HY-123578 | NSC689857 | Inhibitor | 99.49% | Unkown |
| HY-N2524 | Camelliaside A | Ligand | 99.65% | Unkown |
| HY-104066 | Theliatinib | Inhibitor | 99.72% | Unkown |
| HY-109061B | Lazertinib mesylate | Inhibitor | 99.85% | Unkown |
| HY-157581 | MS39 | Degrader | 99.89% | Unkown |
| HY-108016 | Peruvoside | Inhibitor | 99.32% | Unkown |
| HY-10325 | CL-387785 | Inhibitor | 99.31% | Unkown |
| HY-108484 | PP 3 | Inhibitor | 99.20% | Unkown |
| HY-134877 | BAY 2476568 | Inhibitor | 99.88% | Unkown |
| HY-12026 | WZ4002 | Inhibitor | 98.99% | Unkown |
| HY-112097 | E260 | Inhibitor | 99.92% | Unkown |
| HY-13464 | ALK-IN-1 | Inhibitor | 99.42% | Unkown |
| HY-137191 | CH7233163 | Inhibitor | 99.41% | Unkown |
| HY-150611 | EGFR-IN-70 | Inhibitor | 98.12% | Unkown |
| HY-115481 | EphB1-IN-1 | Inhibitor | 99.51% | Unkown |
| HY-N2445 | Flavokawain C | Inhibitor | 99.79% | Unkown |
| HY-147858 | PROTAC EGFR degrader 7 | Degrader | 99.48% | Unkown |
| HY-19729 | Naquotinib | Inhibitor | 98.10% | Unkown |
| HY-107364 | MTX-211 | Inhibitor | 99.81% | Unkown |
| HY-172429 | Enozertinib | Inhibitor | 98.86% | Unkown |
| HY-147219A | SIAIS164018 hydrochloride | Degrader | 98.06% | Unkown |
| HY-156640 | Rocbrutinib | Inhibitor | 99.76% | Unkown |
| HY-103442 | CGP52411 | Inhibitor | 99.82% | Unkown |
| HY-N4201 | β-Hydroxyisovalerylshikonin | Inhibitor | 99.83% | Unkown |
| HY-15772S | Osimertinib-d6 | Inhibitor | 99.70% | Unkown |
| HY-128862 | EGFR-IN-7 | Inhibitor | 99.76% | Unkown |
| HY-128576 | DS21360717 | 99.80% | Unkown | |
| HY-12013 | PD153035 Hydrochloride | Inhibitor | 99.48% | Unkown |
| HY-W018800 | 4(3H)-Quinazolinone | Inhibitor | 99.89% | Unkown |
| HY-162299 | EGFR kinase inhibitor 3 | Inhibitor | 99.03% | Unkown |
| HY-17499 | EGFR-IN-12 | Inhibitor | 99.60% | Unkown |
| HY-B1394 | Khellin | Inhibitor | 99.66% | Unkown |
| HY-15844 | AG-825 | Inhibitor | 98.13% | Unkown |
| HY-13895 | WHI-P154 | Inhibitor | 98.77% | Unkown |
| HY-163094 | EGFR-IN-95 | Inhibitor | 98.76% | Unkown |
| HY-13897 | CNX-2006 | Inhibitor | 98.00% | Unkown |
| HY-12001 | WZ-3146 | Inhibitor | 99.28% | Unkown |
| HY-161275 | BI-4732 | Inhibitor | 98.81% | Unkown |
| HY-130616 | EGFR-IN-11 | Inhibitor | 98.76% | Unkown |
| HY-111415 | EGFR-IN-5 | Inhibitor | 99.49% | Unkown |
| HY-147183B | JBJ-09-063 hydrochloride | Inhibitor | 99.37% | Unkown |
| HY-12010 | BMS-599626 Hydrochloride | Inhibitor | 98.90% | Unkown |
| HY-147941A | MS9427 TFA | Degrader | 98.38% | Unkown |
| HY-161408 | GePhos1 | 98.88% | Unkown | |
| HY-153796 | PROTAC Her3 Degrader-8 | Degrader | 99.60% | Unkown |
| HY-172470 | DSPE-PEG2000-GE11 | 95.29% | Unkown | |
| HY-144304 | PROTAC EGFR degrader 2 | Inhibitor | 95.09% | Unkown |
| HY-18603 | FIIN-3 | Inhibitor | 99.01% | Unkown |
| HY-139617 | Sec61-IN-3 | Inhibitor | 99.22% | Unkown |
| HY-13427 | Allitinib tosylate | Inhibitor | 99.54% | Unkown |
| HY-147942 | MS9449 | Degrader | 98.95% | Unkown |
| HY-136430 | JCN037 | Inhibitor | 99.09% | Unkown |
| HY-161537 | EGFR ligand-9 | Inhibitor | 98.80% | Unkown |
| HY-43533 | Tarlox-TKI | Inhibitor | 98.79% | Unkown |
| HY-153901 | PROTAC EGFR degrader 8 | Degrader | 98.90% | Unkown |
| HY-P2503 | EGFR Protein Tyrosine Kinase Substrate | 99.46% | Unkown | |
| HY-101960A | Tyrphostin A51 | Inhibitor | 99.0% | Unkown |
| HY-110406 | 13(S)-HPODE | Activator | 95.05% | Unkown |
| HY-N1988 | Cucurbitacin IIa | Inhibitor | 99.90% | Unkown |
| HY-N1073 | Wighteone | Inhibitor | 98.71% | Unkown |
| HY-149530 | EGFR-IN-86 | Inhibitor | 99.92% | Unkown |
| HY-P5314 | OK2 | Inhibitor | 99.13% | Unkown |
| HY-117155 | PKI-166 | Inhibitor | 98.92% | Unkown |
| HY-P4082 | ErbB-2-binding peptide-1 | Ligand | 99.52% | Unkown |
| HY-175252 | PROTAC EGFR degrader 14 | Degrader | 99.26% | Unkown |
| HY-146349 | PROTAC EGFR degrader 4 | Degrader | 99.70% | Unkown |
| HY-161633 | PROTAC EGFR degrader 11 | Degrader | 99.20% | Unkown |
| HY-163428 | Perzebertinib | Inhibitor | / | Unkown |
| HY-12029 | WZ8040 | Inhibitor | 98.29% | Unkown |
| HY-147183A | JBJ-09-063 TFA | Inhibitor | 99.64% | Unkown |
| HY-150023 | BI-1622 | Inhibitor | 98.02% | Unkown |
| HY-138627A | AST5902 trimesylate | Inhibitor | 98.75% | Unkown |
| HY-W013857 | Lavendustin C | Inhibitor | 98.17% | Unkown |
| HY-112293 | GW2974 | 99.16% | Unkown | |
| HY-P1828A | EGFRvIII peptide (PEPvIII) TFA | 98.73% | Unkown | |
| HY-177008 | PROTAC HER2 degrader-1 | Degrader | 98.0% | Unkown |
| HY-P11308 | Cys-GE11 | 98.03% | Unkown | |
| HY-79511 | FAAH-IN-2 | Ligand | 99.12% | Unkown |
| HY-101429 | RG13022 | Inhibitor | 96.74% | Unkown |
| HY-123952 | RTC-5 | Inhibitor | 99.37% | Unkown |
| HY-RS04209 | EGFR Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-175839 | PROTAC EGFR degrader 15 | Degrader | 99.23% | Unkown |
| HY-124674A | CCT365623 hydrochloride | Inhibitor | 98.07% | Unkown |
| HY-103566 | LY456236 | Inhibitor | 99.57% | Unkown |
| HY-123035 | Gamendazole | Inhibitor | 99.44% | Unkown |
| HY-15336 | AG 555 | Inhibitor | 98.0% | Unkown |
| HY-157579 | MS154N | 99.30% | Unkown | |
| HY-P10792 | HER2-targeted peptide H6F | 98.85% | Unkown | |
| HY-101219 | VEGFR-IN-1 | Inhibitor | 99.07% | Unkown |
| HY-103440 | EGFR/ErbB-2/ErbB-4 inhibitor-3 | Inhibitor | 96.78% | Unkown |
| HY-161126 | EGFR-IN-98 | Inhibitor | 99.12% | Unkown |
| HY-19985A | (3S,4S)-PF-06459988 | 98.97% | Unkown | |
| HY-101041 | (E)-AG 556 | Inhibitor | 99.91% | Unkown |
| HY-126320 | EGFR-IN-8 | Inhibitor | 98.01% | Unkown |
| HY-164919 | Calotatug ginistinag | Inhibitor | 95.94% | Unkown |
| HY-100214 | EAI001 | Inhibitor | 99.93% | Unkown |
| HY-15769 | WHI-P180 | Inhibitor | 99.84% | Unkown |
| HY-150024 | BI-4142 | Inhibitor | 98.02% | Unkown |
| HY-142283AS | Dosimertinib-d5 mesylate | Inhibitor | 99.50% | Unkown |
| HY-111138 | CZC-8004 | Inhibitor | 99.81% | Unkown |
| HY-112474 | Tyrphostin AG 112 | Inhibitor | 98.31% | Unkown |
| HY-135805B | (Rac)-JBJ-04-125-02 acetate | / | Unkown | |
| HY-112420 | EGFR/ErbB-2-IN-2 | Inhibitor | 99.45% | Unkown |
| HY-131864A | SJF-1528 hemihydrate | Degrader | 98.90% | Unkown |
| HY-P10224A | G7-18NATE TFA | 98.06% | Unkown | |
| HY-12806 | AG1557 | Inhibitor | 99.54% | Unkown |
| HY-142512 | EGFR-IN-24 | Inhibitor | 98.71% | Unkown |
| HY-101450 | PF-6274484 | Inhibitor | 98.76% | Unkown |
| HY-101042 | AG-494 | Inhibitor | 98.69% | Unkown |
| HY-13984 | NT-1 | Inhibitor | 99.40% | Unkown |
| HY-N6577 | Astragaloside VI | 99.95% | Unkown | |
| HY-118532 | Tyrphostin AG30 | Inhibitor | 98.51% | Unkown |
| HY-172920 | Wnt/β-catenin-IN-6 | Inhibitor | 98.34% | Unkown |
| HY-N7424 | 4,7-Dihydroxycoumarin | Inhibitor | 98.25% | Unkown |
| HY-15729A | Rociletinib hydrobromide | Inhibitor | 98.04% | Yes |
| HY-157480 | EGFR/AURKB-IN-1 | Inhibitor | 99.43% | Unkown |
| HY-107459 | (E/Z)-AG490 | Inhibitor | 99.71% | Unkown |
| HY-156284 | EGFR-IN-89 | Inhibitor | 98.75% | Unkown |
| HY-N6932 | Voacamine | 99.64% | Unkown | |
| HY-119944 | JND3229 | Inhibitor | 99.38% | Unkown |
| HY-153110A | Larotinib mesylate hydrate | Inhibitor | 98.66% | Unkown |
| HY-141481 | DP-C-4 | Inhibitor | 98.15% | Unkown |
| HY-156741A | EGFR-IN-87 hydrochloride | Inhibitor | 98.0% | Unkown |
| HY-101522 | CHMFL-EGFR-202 | Inhibitor | 99.75% | Unkown |
| HY-164763 | SHR-A1201 | Inhibitor | 97.35% | Unkown |
| HY-112345 | PD-089828 | Inhibitor | 98.07% | Unkown |
| HY-179572 | STA-013 | Inhibitor | 99.18% | Unkown |
| HY-149889 | EGFR-IN-78 | Inhibitor | 99.57% | Unkown |
| HY-P11078A | LARLLT TFA | 99.89% | Unkown | |
| HY-145960A | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic | Agonist | 97.70% | Unkown |
| HY-161781 | HVH-2930 | Inhibitor | 96.54% | Unkown |
| HY-50896S | Erlotinib-d6 | Inhibitor | 99.84% | Unkown |
| HY-100923 | H-9 Dihydrochloride | Inhibitor | 98.98% | Unkown |
| HY-103441 | JNJ28871063 hydrochloride | Inhibitor | 98.36% | Unkown |
| HY-133780 | Afatinib impurity 11 | Inhibitor | 99.10% | Unkown |
| HY-P1855 | HER2/neu (654-662) GP2 | 98.26% | Unkown | |
| HY-161927 | EGFR-TK-IN-4 | Inhibitor | 99.90% | Unkown |
| HY-101426 | RG14620 | Inhibitor | 99.02% | Unkown |
| HY-143337 | EGFR-IN-47 | Inhibitor | 96.01% | Unkown |
| HY-131686A | Ganglioside GT1b (porcine) ammonium | Activator | 98% | Unkown |
| HY-RS04466 | ERBB2 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-RS04472 | ERBB4 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-100064 | O-Desmethyl gefitinib | Inhibitor | 99.40% | Unkown |
| HY-101006 | Methyl 2,5-dihydroxycinnamate | Inhibitor | 99.77% | Unkown |
| HY-50898S | Lapatinib-d4 | Inhibitor | 99.02% | Unkown |
| HY-15801 | HG-14-10-04 | Inhibitor | 98.53% | Unkown |
| HY-151159 | DHFR-IN-4 | Inhibitor | 99.19% | Unkown |
| HY-N1166 | Tephrosin | 98.02% | Unkown | |
| HY-139997 | DDC-01-163 | Degrader | 99.05% | Unkown |
| HY-162890 | EGFR-IN-122 | Inhibitor | 99.98% | Unkown |
| HY-158149 | T-1-PMPA | Inhibitor | 99.70% | Unkown |
| HY-172414 | Andamertinib | Inhibitor | 99.06% | Unkown |
| HY-170820 | XYD049 | Inhibitor | 99.46% | Unkown |
| HY-157582 | MS39N | Control | 98.0% | Unkown |
| HY-50895S2 | Gefitinib-d3 | Inhibitor | 98.39% | Unkown |
| HY-156872 | MTX-216 | Inhibitor | / | Unkown |
| HY-113599 | Isoprocurcumenol | Activator | 95.41% | Unkown |
| HY-13450 | ZM 449829 | Inhibitor | 99.73% | Unkown |
| HY-112870AS | Firmonertinib-d3 mesylate | 99.00% | Unkown | |
| HY-50895S | Gefitinib-d8 | Inhibitor | 98.42% | Unkown |
| HY-135805A | (Rac)-JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-100962 | (E)-AG 99 | Inhibitor | 98.12% | Unkown |
| HY-19617 | EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-131067 | EMI56 | Inhibitor | 99.36% | Unkown |
| HY-19617A | EGFR-IN-1 hydrochloride | Inhibitor | / | Unkown |
| HY-152852 | Mefatinib free base | Inhibitor | 99.40% | Unkown |
| HY-138627 | AST5902 | Inhibitor | / | Unkown |
| HY-147183 | JBJ-09-063 | Inhibitor | / | Unkown |
| HY-115716 | EGFR-IN-17 | Inhibitor | 98.18% | Unkown |
| HY-132842A | (S)-Sunvozertinib | Inhibitor | 99.05% | Unkown |
| HY-130608 | Mutated EGFR-IN-3 | Inhibitor | / | Unkown |
| HY-147941 | MS9427 | Degrader | 95.29% | Unkown |
| HY-139300A | Epitinib succinate | Inhibitor | 99.01% | Unkown |
| HY-P3744 | pp60v-src Autophosphorylation site | 99.93% | Unkown | |
| HY-15772S1 | Osimertinib-13C,d3 | 99.14% | Unkown | |
| HY-183682 | AZ14289671 | Inhibitor | 98.99% | Unkown |
| HY-101958 | Tyrphostin 25 | Inhibitor | 99.00% | Unkown |
| HY-P992138 | Vadalentamig | Inhibitor | 95.29% | Unkown |
| HY-135805 | JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-150610 | EGFR-IN-69 | Inhibitor | 99.58% | Unkown |
| HY-19617B | EGFR-IN-1 TFA | Inhibitor | 99.38% | Unkown |
| HY-147219 | SIAIS164018 | Degrader | / | Unkown |
| HY-P992128 | Rinumafusp alfa | Inhibitor | 97.09% | Unkown |
| HY-U00002 | ZD-4190 | Inhibitor | 98.08% | Unkown |
| HY-P2673 | Lys-Arg-Thr-Leu-Arg-Arg | / | Unkown | |
| HY-145960 | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 | Agonist | 99.39% | Unkown |
| HY-164387 | Sutetinib | Inhibitor | 99.27% | Unkown |
| HY-101007A | (+)-Tyrphostin B44 | Inhibitor | 99.10% | Unkown |
| HY-E70715 | ERBB2 775YVMA776 Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-138072 | EMI1 | Inhibitor | 99.45% | Unkown |
| HY-103439 | GW583340 dihydrochloride | Inhibitor | / | Unkown |
| HY-10346A | AV-412 free base | Inhibitor | 98.10% | Unkown |
| HY-161618 | MJ04 | Inhibitor | 98.08% | Unkown |
| HY-13272S2 | Dacomitinib-d10 dihydrochloride | Inhibitor | ≥95.0% | Unkown |
| HY-12008S | Erlotinib-d6 hydrochloride | Inhibitor | 98.13% | Unkown |
| HY-100499 | Tyrphostin AG 528 | Inhibitor | 98.0% | Unkown |
| HY-155005 | EGFR mutant-IN-2 | Inhibitor | 97.0% | Unkown |
| HY-155358 | Os30 | Inhibitor | 98.34% | Unkown |
| HY-144677 | pan-HER-IN-2 | Inhibitor | 98.10% | Unkown |
| HY-N6651 | Isocryptotanshinone | Inhibitor | ≥98.0% | Unkown |
| HY-108486 | Herbimycin A | Degrader | 99% | Unkown |
| HY-131088 | N3-PEG8-Phe-Lys-PABC-Gefitinib | Inhibitor | / | Unkown |
| HY-12872B | Nazartinib S-enantiomer | 95.10% | Unkown | |
| HY-B0794A | AZ7550 hydrochloride | Inhibitor | 98.66% | Unkown |
| HY-162254 | EGFR/ACK1-IN-1 | Inhibitor | 98.19% | Unkown |
| HY-149636 | Multi-target kinase inhibitor 2 | Inhibitor | 99.82% | Unkown |
| HY-126850 | 4-Epidoxycycline | / | Unkown | |
| HY-50895S1 | Gefitinib-d6 | Inhibitor | 98.2% | Unkown |
| HY-158310 | SOS1/EGFR-IN-1 | Inhibitor | 99.54% | Unkown |
| HY-157413 | YS-67 | Inhibitor | 99.41% | Unkown |
| HY-131088A | N3-PEG8-Phe-Lys-PABC-Gefitinib TFA | Inhibitor | / | Unkown |
| HY-153111 | EGFR/HER2-IN-9 | Inhibitor | 98.73% | Unkown |
| HY-170928 | DA-0157 | Inhibitor | 99.59% | Unkown |
| HY-156741 | EGFR-IN-87 | Inhibitor | / | Unkown |
| HY-151048 | JBJ-07-149 | Inhibitor | 99.09% | Unkown |
| HY-129510 | 4-Methyl erlotinib | Inhibitor | 99.34% | Unkown |
| HY-111452 | EGFR-IN-85 | Inhibitor | / | Unkown |
| HY-N10103 | Neoschaftoside | Modulator | 98.04% | Unkown |
| HY-14347 | EBE-A22 | Control | 99.76% | Unkown |
| HY-183068 | AP4-43 | Inhibitor | 99.76% | Unkown |
| HY-15772S3 | Asandeutertinib | Inhibitor | 99.75% | Unkown |
| HY-108931 | AG 1406 | Inhibitor | 99.03% | Unkown |
| HY-126319 | SU5204 | Inhibitor | 99.46% | Unkown |
| HY-P2673A | Lys-Arg-Thr-Leu-Arg-Arg acetate | / | Unkown | |
| HY-155285 | YS-363 | Inhibitor | 99.52% | Unkown |
| HY-156912 | Tyrosine kinase-IN-7 | Inhibitor | 99.25% | Unkown |
| HY-10261S | Afatinib-d6 | Inhibitor | 99.0% | Unkown |
| HY-147858A | PROTAC EGFR degrader 7 diTFA | Degrader | 97.15% | Unkown |
| HY-B0794S | AZ7550-d5 | Inhibitor | / | Unkown |
| HY-P990698 | Umizortamig | 96.90% | Unkown | |
| HY-21291 | SU-4313 | Modulator | 99.31% | Unkown |
| HY-123766 | EGFR-IN-99 | Inhibitor | 98.09% | Unkown |
| HY-W001520 | 1-Methyl-1H-pyrrolo[2,3-b]pyridine | / | Unkown | |
| HY-W109039 | EGFR ligand-15 | 97.03% | Unkown | |
| HY-164476 | ES-072 | Inhibitor | 98.05% | Unkown |
| HY-12872A | Nazartinib mesylate | Inhibitor | / | Unkown |
| HY-P992130 | Rolditamig | Inhibitor | 95.26% | Unkown |
| HY-185832 | SYS6010 | Inhibitor | / | Unkown |
| HY-185816 | TQB2102 | Inhibitor | / | Unkown |
| HY-18750A | Zorifertinib hydrochloride | Inhibitor | / | Unkown |
| HY-19981B | Derazantinib dihydrochloride | Inhibitor | / | Unkown |
| HY-135914 | JBJ-02-112-05 | Inhibitor | / | Unkown |
| HY-100520 | EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-142283 | Dosimertinib | Inhibitor | / | Unkown |
| HY-143734 | HER2-IN-6 | / | Unkown | |
| HY-B0793S1 | AZ-5104-d2 | Inhibitor | / | Unkown |
| HY-132883 | EGFR/CSC-IN-1 | Inhibitor | / | Unkown |
| HY-144048 | EGFR-IN-31 | / | Unkown | |
| HY-139920A | Oritinib mesylate | Inhibitor | / | Unkown |
| HY-163354 | EGFR-IN-103 | Inhibitor | / | Unkown |
| HY-128860 | Mutated EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-125841 | EGFR mutant-IN-1 | Inhibitor | / | Unkown |
| HY-168968S | ZJY-54 | Inhibitor | / | Unkown |
| HY-112806 | ST8155AA1 | / | Unkown | |
| HY-138746 | EGFR-IN-15 | Inhibitor | 96.21% | Unkown |
| HY-131066 | EMI48 | Inhibitor | 99.45% | Unkown |
| HY-147407 | Imbotolimod | Inhibitor | / | Unkown |
| HY-152852A | Mefatinib | Inhibitor | 98.90% | Unkown |
| HY-123726 | ErbB-1/ErbB-2 tyrosine kinase-IN-1 | / | Unkown | |
| HY-10407G | SU 5402 (GMP) | Inhibitor | / | Unkown |
| HY-137433A | Befotertinib mesylate | Inhibitor | / | Unkown |
| HY-115951 | EGFR/HER2-IN-2 | Inhibitor | / | Unkown |
| HY-147303 | Sacibertinib | Inhibitor | / | Unkown |
| HY-152852S | Mefatinib-d6 free base | Inhibitor | / | Unkown |
| HY-10368 | EGFR/VEGFR2-IN-4 | Inhibitor | / | Unkown |
| HY-182264 | Masoprocol tetrapivalate | Inhibitor | / | Unkown |
| HY-142283CS | N-Methyl-dosimertinib-d5 | / | Unkown | |
| HY-181251 | EGFR-IN-195 | Inhibitor | / | Unkown |
| HY-152144 | EGFR-IN-75 | Inhibitor | / | Unkown |
| HY-151981 | EGFR-IN-74 | Inhibitor | / | Unkown |
| HY-152019 | EGFR/C797S-IN-1 | Inhibitor | / | Unkown |
| HY-183310 | EGFR-IN-210 | Inhibitor | / | Unkown |
| HY-161602 | EGFR/HER2-IN-13 | Inhibitor | / | Unkown |
| HY-161146 | EGFR-IN-100 | Inhibitor | / | Unkown |
| HY-P990049A | Becotatug (powder) | Inhibitor | / | Unkown |
| HY-172961 | EGFR-IN-162 | Inhibitor | / | Unkown |
| HY-135216 | Antiproliferative agent-54 | Inhibitor | / | Unkown |
| HY-175864 | EGFR-IN-173 | Inhibitor | / | Unkown |
| HY-173188 | EGFR-IN-154 | Inhibitor | / | Unkown |
| HY-172623 | EGFR/HER2-IN-17 | Inhibitor | / | Unkown |
| HY-13595R | Chrysophanol (Standard) | Inhibitor | / | Unkown |
| HY-E70703 | EGFR d752-759 Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-163453 | HER2-IN-19 | Inhibitor | / | Unkown |
| HY-147798 | EGFR/HER2/CDK9-IN-3 | Inhibitor | / | Unkown |
| HY-181776 | c-Met-IN-31 | Inhibitor | / | Unkown |
| HY-131710 | PDE5-IN-3 | Inhibitor | / | Unkown |
| HY-179600 | Dyrk1A-IN-16 | Inhibitor | / | Unkown |
| HY-187533 | EGFR AUTOTAC-1 | Degrader | / | Unkown |
| HY-174232 | EGFR/CA-IX-IN-1 | Inhibitor | / | Unkown |
| HY-180536 | HB-EGF-IN-1 | Inhibitor | / | Unkown |
| HY-172897 | EGFR/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-175635 | EGFR/VEGFR2-IN-6 | Inhibitor | / | Unkown |
| HY-175531 | EGFR-IN-169 | Inhibitor | / | Unkown |
| HY-183373 | EGFR/PARP-1-IN-1 | Inhibitor | / | Unkown |
| HY-161269 | EGFR-IN-101 | Inhibitor | / | Unkown |
| HY-158988 | EGFR-IN-114 | Inhibitor | / | Unkown |
| HY-E70711 | EGFR T790M/L858R Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-P11944 | Peptide 22 | Chemical | / | Unkown |
| HY-161145 | EGFR/microtubule-IN-1 | Inhibitor | / | Unkown |
| HY-161045 | T-1-DOCA | Inhibitor | / | Unkown |
| HY-RS04470 | Erbb3 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-147996 | EGFR-IN-67 | Inhibitor | / | Unkown |
| HY-144441 | NSC81111 | Inhibitor | / | Unkown |
| HY-181657 | EGFR-IN-200 | Inhibitor | / | Unkown |
| HY-E70698 | EGFR d746-750/C797S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-187838S | Adonertinib | Inhibitor | / | Unkown |
| HY-181775 | VEGFR-2/c-Met/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-171884 | BI-8128 | Inhibitor | / | Unkown |
| HY-P5258 | Oligopeptide-41 | Inducer | 98.05% | Unkown |
| HY-153744 | JGK-068S | Inhibitor | / | Unkown |
| HY-172091 | CZY43 | Degrader | / | Unkown |
| HY-147796 | EGFR/HER2/CDK9-IN-1 | Inhibitor | / | Unkown |
| HY-168492 | TrxR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-146238 | EGFR/HER2/TS-IN-1 | Inhibitor | / | Unkown |
| HY-144054 | EGFR-IN-37 | Inhibitor | / | Unkown |
| HY-185227 | EphB4-IN-1 | Inhibitor | / | Unkown |
| HY-179529 | EGFR/InhA-IN-1 | Inhibitor | / | Unkown |
| HY-162360 | EGFR-IN-109 | Inhibitor | / | Unkown |
| HY-P10659 | Self-assembling peptide pY1 | / | Unkown | |
| HY-187334 | EGFR-IN-216 | Inhibitor | / | Unkown |
| HY-179522 | EGFR-IN-186 | Inhibitor | / | Unkown |
| HY-18213 | EGFR-IN-9 | Inhibitor | 98.69% | Unkown |
| HY-174841 | EGFR/HER2-IN-19 | Inhibitor | / | Unkown |
| HY-163434 | PRMT5/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-168469 | EGFR-IN-148 | Inhibitor | / | Unkown |
| HY-183277 | EGFR-IN-209 | Inhibitor | / | Unkown |
| HY-160564 | ZNL-0056 | Inhibitor | / | Unkown |
| HY-156470 | Multi-kinase-IN-6 | Inhibitor | / | Unkown |
| HY-178942 | EGFR/VEGFR2-IN-9 | Inhibitor | / | Unkown |
| HY-103566A | LY456236 free base | Inhibitor | / | Unkown |
| HY-162099 | VEGFR-IN-4 | Inhibitor | / | Unkown |
| HY-B0793G | AZ-5104 (GMP) | Inhibitor | / | Unkown |
| HY-172877 | EGFR/BRAFV600E-IN-5 | Inhibitor | / | Unkown |
| HY-178448 | EGFR-IN-178 | Inhibitor | / | Unkown |
| HY-171252 | EGFR-IN-145 | Inhibitor | / | Unkown |
| HY-146170 | Anticancer agent 69 | Inhibitor | / | Unkown |
| HY-W008914 | (E/Z)-CP-724714 | Inhibitor | / | Unkown |
| HY-173367 | Anticancer agent 271 | Inhibitor | / | Unkown |
| HY-P5742 | ELAAWCRWGFLLALLPPGIAG | / | Unkown | |
| HY-181056 | EGFR/COX-2-IN-3 | Inhibitor | 99.76% | Unkown |
| HY-162589 | Lw13 | Inhibitor | / | Unkown |
| HY-147741 | DPPY | Inhibitor | / | Unkown |
| HY-144052 | EGFR-IN-35 | Inhibitor | / | Unkown |
| HY-175805 | EGFR/HDAC-IN-2 | Inhibitor | / | Unkown |
| HY-E70704 | EGFR G719C Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-144097 | HER2-IN-8 | Inhibitor | / | Unkown |
| HY-N1988R | Cucurbitacin IIa (Standard) | Inhibitor | / | Unkown |
| HY-147794 | CDK9-IN-41 | Inhibitor | 98.84% | Unkown |
| HY-144760 | EGFR-IN-3 | Inducer | / | Unkown |
| HY-185833 | ADC Control Human IgG1-JSSW-001 | Inhibitor | / | Unkown |
| HY-178242 | PROTAC EGFR degrader 16 | Degrader | / | Unkown |
| HY-163657 | HER2-IN-20 | Inhibitor | / | Unkown |
| HY-158153 | EGFR-IN-108 | Inhibitor | / | Unkown |
| HY-178311 | EGFR Ligand-Linker Conjugates 4 | Ligand | / | Unkown |
| HY-181502 | EGFR-IN-197 | Inhibitor | / | Unkown |
| HY-172534 | BPN-01 | Substrate | / | Unkown |
| HY-175171 | Anticancer agent 276 | Inhibitor | / | Unkown |
| HY-157402 | Topoisomerase II/EGFR-IN-1 | / | Unkown | |
| HY-181714 | EGFR-IN-203 | Inhibitor | / | Unkown |
| HY-P11752 | Cyclo(KLARLLT) | Ligand | / | Unkown |
| HY-184719 | VEGFR-2-IN-88 | Inhibitor | / | Unkown |
| HY-178057 | EGFR-IN-176 | Inhibitor | / | Unkown |
| HY-163418 | HER2-IN-17 | Inhibitor | / | Unkown |
| HY-RS04467 | Erbb2 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-177009 | Tucatinib analog B | Ligand | / | Unkown |
| HY-172469 | DSPE-PEG1000-GE11 | / | Unkown | |
| HY-P11761 | HYNIC-H10F | Ligand | / | Unkown |
| HY-P5745A | TYVPANASL TFA | / | Unkown | |
| HY-158313 | PROTAC EGFR degrader 13 | Inhibitor | / | Unkown |
| HY-184720 | VEGFR-2-IN-89 | Inhibitor | / | Unkown |
| HY-179098 | Multi-target kinase-IN-8 | Inhibitor | / | Unkown |
| HY-50896S1 | Erlotinib-13C6 | Inhibitor | / | Unkown |
| HY-160087 | SG3376 | Ligand | / | Unkown |
| HY-181097 | EGFR-IN-192 | Inhibitor | / | Unkown |
| HY-50898S2 | Lapatinib-d5 | Inhibitor | / | Unkown |
| HY-175809 | SRT6 | Inhibitor | / | Unkown |
| HY-169346 | Pred17 | Inhibitor | / | Unkown |
| HY-173038 | EGFR-IN-151 | Inhibitor | / | Unkown |
| HY-155074 | EGFR-IN-79 | Inhibitor | / | Unkown |
| HY-151377 | RET-IN-19 | Inhibitor | / | Unkown |
| HY-170787 | TZEP7 | Inhibitor | / | Unkown |
| HY-157398 | EGFR T790M/L858R-IN-3 | Inhibitor | / | Unkown |
| HY-149633 | EGFR/HER2/DHFR-IN-3 | Inhibitor | / | Unkown |
| HY-B0793GL | AZ-5104 (GMP Like) | Inhibitor | / | Unkown |
| HY-151156 | EGFR/HER2-IN-6 | Inhibitor | / | Unkown |
| HY-184301 | EGFR/HER2-IN-20 | Inhibitor | / | Unkown |
| HY-184311 | EGFR-IN-214 | Inhibitor | / | Unkown |
| HY-50898S3 | Lapatinib-d4-1 | Inhibitor | / | Unkown |
| HY-172104 | EGFR-IN-143 | Inhibitor | / | Unkown |
| HY-143445 | EGFR-IN-48 | Inhibitor | / | Unkown |
| HY-175316 | EGFR-IN-168 | Inhibitor | / | Unkown |
| HY-172966 | EG31 | Inhibitor | / | Unkown |
| HY-149401 | EGFR-IN-82 | Inhibitor | / | Unkown |
| HY-P1085 | Epidermal Growth Factor Receptor Peptide (985-996) | Chemical | / | Unkown |
| HY-170497 | EGFR-IN-140 | Inhibitor | / | Unkown |
| HY-172795 | EGFR-IN-158 | Inhibitor | / | Unkown |
| HY-155118 | EGFR-IN-81 | Inhibitor | / | Unkown |
| HY-157166 | EGFR kinase inhibitor 2 | Inhibitor | / | Unkown |
| HY-163402 | EGFR-IN-108 chloride | Inhibitor | / | Unkown |
| HY-P11757 | Cyclo[K(N3)larllt] | Ligand | / | Unkown |
| HY-163377 | AZ5385 | Inhibitor | / | Unkown |
| HY-159519 | EGFR/HER2-IN-16 | Inhibitor | / | Unkown |
| HY-180922 | EGFR kinase-IN-8 | Inhibitor | / | Unkown |
| HY-170665 | EGFR T790M/L858R-IN-9 | Inhibitor | / | Unkown |
| HY-15268 | PP487 | Inhibitor | / | Unkown |
| HY-182005 | EGFR/VEGFR2-IN-12 | Inhibitor | / | Unkown |
| HY-103439A | GW583340 | Inhibitor | / | Unkown |
| HY-402309 | IGF-1R modulator 1 | Modulator | / | Unkown |
| HY-175297 | EGFR T790M/VEGFR-2-IN-1 | Inhibitor | / | Unkown |
| HY-146228 | HSP90-IN-13 | Inhibitor | / | Unkown |
| HY-103437 | EGFR-IN-80 | Inhibitor | / | Unkown |
| HY-176744 | HER2-IN-22 | Inhibitor | / | Unkown |
| HY-157399 | EGFR/HER2-IN-10 | Inhibitor | / | Unkown |
| HY-13314A | Tesevatinib tosylate | Inhibitor | / | Unkown |
| HY-147862 | EGFR-IN-62 | Inhibitor | / | Unkown |
| HY-178157 | Multi-target kinase-IN-7 | Inhibitor | / | Unkown |
| HY-103630 | PROTAC Her3 Degrader-2 | Degrader | / | Unkown |
| HY-142680 | EGFR-IN-23 | Inhibitor | / | Unkown |
| HY-162323 | EGFR-IN-106 | Inhibitor | / | Unkown |
| HY-157994 | EGFR WT/T790M-IN-2 | Inhibitor | / | Unkown |
| HY-168577 | KRAS G12D inhibitor 25 | Degrader | / | Unkown |
| HY-146239 | EGFR/HER2/TS-IN-2 | Inhibitor | / | Unkown |
| HY-144051 | EGFR-IN-34 | Inhibitor | / | Unkown |
| HY-147992 | EGFR/HER2-IN-4 | Inhibitor | / | Unkown |
| HY-180541 | EGFR-IN-190 | Inhibitor | / | Unkown |
| HY-147997 | EGFR-IN-68 | Inhibitor | / | Unkown |
| HY-175009 | MRC-G-001 | Inhibitor | / | Unkown |
| HY-163371 | EGFR WT/T790M-IN-1 | Inhibitor | / | Unkown |
| HY-103629 | PROTAC Her3 Degrader-1 | Inhibitor | / | Unkown |
| HY-137028 | 2′-Thioadenosine | Inhibitor | / | Unkown |
| HY-161603 | EGFR/HER2-IN-14 | Inhibitor | / | Unkown |
| HY-50898S5 | Lapatinib-13C,d7 | Inhibitor | / | Unkown |
| HY-142679 | EGFR-IN-22 | Inhibitor | / | Unkown |
| HY-174415 | ZSH-2117 | Degrader | / | Unkown |
| HY-163880 | EGFR-IN-119 | Inhibitor | / | Unkown |
| HY-162483 | EGFR kinase inhibitor 6 | Inhibitor | / | Unkown |
| HY-143901 | EGFR-IN-40 | Inhibitor | / | Unkown |
| HY-156116 | EGFR/CDK2-IN-4 | Inhibitor | / | Unkown |
| HY-18957A | rel-Lifirafenib | Control | / | Unkown |
| HY-P5742A | ELAAWCRWGFLLALLPPGIAG TFA | / | Unkown | |
| HY-149824 | EGFR T790M/L858R-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-100636A | Gefitinib N-oxide hydrochloride | Inhibitor | / | Unkown |
| HY-161731 | DS08701581 | Inhibitor | / | Unkown |
| HY-164392 | TAS-121 | Inhibitor | / | Unkown |
| HY-178119 | HER4/HER2-IN-1 | Inhibitor | / | Unkown |
| HY-183120 | EGFR T790M/FAK-IN-2 | Inhibitor | / | Unkown |
| HY-161067 | EGFR-IN-96 | Inhibitor | / | Unkown |
| HY-18298 | PD 173955 analog 1 | Inhibitor | / | Unkown |
| HY-107450 | PROTAC Her3-binding moiety 2 | Inhibitor | / | Unkown |
| HY-181777 | Mal-Pip-ValCit-PAB-AZ7550 | Inhibitor | / | Unkown |
| HY-181093 | EGFR-IN-191 | Inhibitor | / | Unkown |
| HY-180154 | EGFR/BRAFV600E-IN-6 | Inhibitor | / | Unkown |
| HY-169309 | EGFR-IN-133 | Inhibitor | / | Unkown |
| HY-167948 | Dacomitinib metabolite M1/2 | Inhibitor | / | Unkown |
| HY-163860 | EGFR-TK-IN-3 | Inhibitor | / | Unkown |
| HY-137786 | EGFR-IN-16 | Inhibitor | / | Unkown |
| HY-161320 | EGFR-IN-105 | Inhibitor | / | Unkown |
| HY-178939 | EGFR-IN-181 | Inhibitor | / | Unkown |
| HY-144445 | NSC114126 | Inhibitor | / | Unkown |
| HY-164503 | Neptinib | Inhibitor | / | Unkown |
| HY-158154 | EGFR-IN-110 | Inhibitor | / | Unkown |
| HY-189142 | EGFR-IN-217 | Inhibitor | / | Unkown |
| HY-183788 | EGFR-IN-212 | Inhibitor | / | Unkown |
| HY-182031 | JS04 | Inhibitor | / | Unkown |
| HY-156033 | EGFR-IN-88 | Inhibitor | / | Unkown |
| HY-169568 | EGFR-IN-147 | Inhibitor | / | Unkown |
| HY-149407 | Multi-kinase-IN-4 | Inhibitor | / | Unkown |
| HY-N9684 | Degalactotigonin | Inhibitor | / | Unkown |
| HY-150908 | Brigatinib A | Ligand | / | Unkown |
| HY-116091 | EGFR-IN-451 | Inhibitor | / | Unkown |
| HY-138627B | AST5902 mesylate | Inhibitor | / | Unkown |
| HY-146473 | EGFR-IN-53 | Inhibitor | / | Unkown |
| HY-168073 | EGFR/VEGFR2-IN-1 | Inhibitor | / | Unkown |
| HY-P1828 | EGFRvIII peptide (PEPvIII) | / | Unkown | |
| HY-163006 | EGFR/c-Met-IN-1 | Inhibitor | / | Unkown |
| HY-176556 | EGFR-IN-167 | Inhibitor | / | Unkown |
| HY-169427 | FRF-06-057 | Inhibitor | / | Unkown |
| HY-172111 | EGFR-IN-144 | Inhibitor | / | Unkown |
| HY-144444 | NSC381467 | Inhibitor | / | Unkown |
| HY-149846 | SIQ17 | Inhibitor | / | Unkown |
| HY-179485 | EGFR/VEGFR2-IN-10 | Inhibitor | / | Unkown |
| HY-178442 | EGFR-IN-179 | Inhibitor | / | Unkown |
| HY-172156 | EGFR-TK-IN-5 | Inhibitor | / | Unkown |
| HY-149518 | EGFR/BRAFV600E-IN-3 | Inhibitor | / | Unkown |
| HY-100663 | Gefitinib impurity 2 | 99.56% | Unkown | |
| HY-147248 | Opadotina | Inhibitor | / | Unkown |
| HY-138298D | Trastuzumab deruxtecan (DAR6) | Inhibitor | / | Unkown |
| HY-17654 | BIEGi-1 | Inhibitor | / | Unkown |
| HY-112823S | Almonertinib-d6 | Inhibitor | / | Unkown |
| HY-P12120 | ErbB-2-binding peptide-2 | Ligand | / | Unkown |
| HY-164413 | CLM3 | Inhibitor | / | Unkown |
| HY-183123 | EGFR T790M/FAK-IN-1 | Inhibitor | / | Unkown |
| HY-P10995 | TAT-327 | Inhibitor | / | Unkown |
| HY-162602 | EGFR-IN-115 | Inhibitor | / | Unkown |
| HY-146138 | EGFR-IN-57 | Inhibitor | / | Unkown |
| HY-168559 | EGFR-IN-131 | Inhibitor | / | Unkown |
| HY-147825 | EGFR/BRAFV600E-IN-1 | Inhibitor | / | Unkown |
| HY-155227 | ALK/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-144049 | EGFR-IN-32 | Inhibitor | / | Unkown |
| HY-178313 | EGFR ligand-18 | Degrader | / | Unkown |
| HY-182817 | Len-604 | Inhibitor | / | Unkown |
| HY-156991 | NODAGA-NHS | / | Unkown | |
| HY-156114 | EGFR/CDK2-IN-2 | Inhibitor | / | Unkown |
| HY-112334 | EGFR-IN-198 | Inhibitor | / | Unkown |
| HY-177380 | EGFR ligand-14-PEG3-Boc | / | Unkown | |
| HY-178440 | EGFR/COX-2-IN-2 | Inhibitor | / | Unkown |
| HY-175292 | EGFR WT/T790M-IN-3 | Inhibitor | / | Unkown |
| HY-160613 | EGFR/HER2-IN-11 | Inhibitor | / | Unkown |
| HY-163000 | EGFR-IN-129 | Inhibitor | / | Unkown |
| HY-170543 | Dual Galectin-3/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-RS04471 | Erbb3 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-173492 | EGFR-IN-156 | Inhibitor | / | Unkown |
| HY-178005 | EGFR-IN-174 | Inhibitor | / | Unkown |
| HY-158177 | EGFR T790M/L858R-IN-6 | Inhibitor | / | Unkown |
| HY-173218 | anti-NSCLC agent-1 | Inhibitor | / | Unkown |
| HY-179143 | EGFR-IN-185 | Inhibitor | / | Unkown |
| HY-178955 | EGFR-IN-182 | Inhibitor | / | Unkown |
| HY-10261AS | Afatinib-d6 dimaleate | Inhibitor | / | Unkown |
| HY-180917 | PROTAC EGFR degrader 17 | Degrader | / | Unkown |
| HY-E70709 | EGFR T790M Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-W714853 | (+)-Theta-cypermethrin | Ligand | / | Unkown |
| HY-183292 | SH-1092 | Inhibitor | / | Unkown |
| HY-168627 | EGFR-IN-135 | Inhibitor | / | Unkown |
| HY-100064S1 | O-Desmethyl gefitinib-d6 | Inhibitor | / | Unkown |
| HY-156639 | EGFR/ErbB-2 inhibitor-1 | Inhibitor | / | Unkown |
| HY-165394 | Melafolone | Inhibitor | / | Unkown |
| HY-156097 | Anticancer agent 158 | Inhibitor | / | Unkown |
| HY-158178 | EGFR T790M/L858R-IN-7 | Inhibitor | / | Unkown |
| HY-163726 | GLUT1/EGFR-IN-1 | Inhibitor | 99.75% | Unkown |
| HY-143246 | EGFR kinase inhibitor 1 | Inhibitor | / | Unkown |
| HY-P11078 | LARLLT | / | Unkown | |
| HY-151154 | EGFR/HER2/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-142681 | EGFR-IN-28 | Inhibitor | / | Unkown |
| HY-P10648 | Herceptide | / | Unkown | |
| HY-179049 | EGFR/tubulin-IN-1 | Inhibitor | / | Unkown |
| HY-151882 | EGFR-IN-73 | Inhibitor | / | Unkown |
| HY-168876 | AZ14240475 | Inhibitor | / | Unkown |
| HY-146423 | PROTAC EGFR degrader 6 | Degrader | / | Unkown |
| HY-147967 | EGFR-IN-63 | Inhibitor | / | Unkown |
| HY-180242 | EGFR/CDK2-IN-5 | Inhibitor | / | Unkown |
| HY-144056 | EGFR-IN-39 | Inhibitor | / | Unkown |
| HY-176788 | EGFR Ligand-Linker Conjugates 1 | Inhibitor | / | Unkown |
| HY-189075 | I-0436650 | Inhibitor | / | Unkown |
| HY-143733 | HER2-IN-5 | Inhibitor | / | Unkown |
| HY-158176 | EGFR T790M/L858R-IN-5 | Inhibitor | / | Unkown |
| HY-142519 | EGFR-IN-27 | Inhibitor | / | Unkown |
| HY-185276 | EGFR-IN-204 | Inhibitor | 98.57% | Unkown |
| HY-N3634 | Corylifol C | / | Unkown | |
| HY-161923 | EGFR-IN-120 | Inhibitor | / | Unkown |
| HY-171443 | Lyso-Monosialoganglioside GM3 | Inhibitor | / | Unkown |
| HY-181829 | Ctx-L3 | Degrader | / | Unkown |
| HY-19730A | Olmutinib hydrochloride | Inhibitor | / | Unkown |
| HY-163663 | AZ14133346 | Inhibitor | / | Unkown |
| HY-182064 | EGFR-IN-206 | Inhibitor | / | Unkown |
| HY-170968 | EGFR-IN-150 | Inhibitor | / | Unkown |
| HY-176938 | AfaPhos1 | Inhibitor | / | Unkown |
| HY-E70701 | EGFR d747-749/A750P Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-184497 | PROTAC EGFR degrader 18 | Degrader | / | Unkown |
| HY-127067 | Yuanhuadin | Inhibitor | / | Unkown |
| HY-178116 | HER2-IN-23 | Inhibitor | / | Unkown |
| HY-162891 | EGFR-IN-123 | Inhibitor | / | Unkown |
| HY-147802 | EGFR-IN-59 | Inhibitor | / | Unkown |
| HY-141486A | PROTAC PARP/EGFR ligand 1 | / | Unkown | |
| HY-164056 | EGFR T790M/L858R-IN-8 | Inhibitor | 99.20% | Unkown |
| HY-151162 | HER2-IN-12 | Inhibitor | / | Unkown |
| HY-P10686 | CH401 peptide | / | Unkown | |
| HY-174231 | EGFR-IN-163 | Inhibitor | / | Unkown |
| HY-168151 | EGFR-IN-128 | Inhibitor | / | Unkown |
| HY-155178 | Antiproliferative agent-34 | Inhibitor | / | Unkown |
| HY-184274 | EGFR/c-SRC-IN-1 | Inhibitor | / | Unkown |
| HY-150782 | UNC-CA359 | Inhibitor | / | Unkown |
| HY-138298C | Trastuzumab deruxtecan (DAR4) | Inhibitor | / | Unkown |
| HY-177270 | CHNQD-01281 | Modulator | / | Unkown |
| HY-159101 | EP26 | Inhibitor | / | Unkown |
| HY-13272S3 | Dacomitinib-d10 | Inhibitor | / | Unkown |
| HY-179140 | EGFR/VEGFR2-IN-8 | Inhibitor | / | Unkown |
| HY-114535 | Jaceidin | Inhibitor | / | Unkown |
| HY-146782 | EGFR-IN-49 | Inhibitor | / | Unkown |
| HY-RS04469 | ERBB3 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-183253 | DL149 | Ligand | / | Unkown |
| HY-149344 | Anticancer agent 133 | Inhibitor | / | Unkown |
| HY-168112 | EGFR-IN-127 | Inhibitor | / | Unkown |
| HY-173118 | EGFR-IN-152 | Inhibitor | / | Unkown |
| HY-149275 | PKM2/PDK1-IN-1 | Inhibitor | / | Unkown |
| HY-168623 | EGFR-IN-134 | Inhibitor | / | Unkown |
| HY-181142 | Antitumor agent-213 | / | Unkown | |
| HY-161866 | EGFR-IN-118 | Inhibitor | / | Unkown |
| HY-P11590 | WGYRGFYC | Ligand | / | Unkown |
| HY-142678 | EGFR-IN-21 | Inhibitor | / | Unkown |
| HY-175257 | Theophylline-platinum(IV) prodrug-1 | Inhibitor | / | Unkown |
| HY-182914 | NGI-189 | Inhibitor | 99.29% | Unkown |
| HY-170661 | EGFR-IN-142 | Inhibitor | / | Unkown |
| HY-142283BS | N-Desmethyl dosimertinib-d5 | / | Unkown | |
| HY-161031 | EGFR-IN-93 | Inhibitor | / | Unkown |
| HY-172471 | DSPE-PEG5000-GE11 | / | Unkown | |
| HY-144794 | EGFR-IN-46 | Inhibitor | / | Unkown |
| HY-P11613 | DOTA-WC8 | Ligand | / | Unkown |
| HY-116059 | EGFR-IN-199 | Inhibitor | / | Unkown |
| HY-180965 | Pro-PEG3-BA | Degrader | / | Unkown |
| HY-184116 | A2AR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-158969 | EGFR-IN-113 | Inhibitor | / | Unkown |
| HY-181491 | Tubulin-IN-64 | Inhibitor | / | Unkown |
| HY-101960 | (Z)-Tyrphostin A51 | Inhibitor | / | Unkown |
| HY-175608 | EGFR-IN-171 | Inhibitor | / | Unkown |
| HY-E70696 | EGFR C797S/L858R Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-162148 | HNPMI | Inhibitor | 99.57% | Unkown |
| HY-180964 | Lys-PEG3-BA | Degrader | / | Unkown |
| HY-112405 | BPIQ-I | Inhibitor | / | Unkown |
| HY-155969 | EGFR-IN-83 | Inhibitor | / | Unkown |
| HY-161891 | EGFR/Akt-IN-1 | Inhibitor | / | Unkown |
| HY-162623 | EGFR/HER2-IN-15 | Inhibitor | / | Unkown |
| HY-13524A | AG-1478 hydrochloride | Inhibitor | / | Unkown |
| HY-RS04211 | Egfr Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-101959 | Tyrphostin AG213 | Inhibitor | / | Unkown |
| HY-15772GL | Osimertinib (GMP Like) | Inhibitor | / | Unkown |
| HY-P2548 | pp60 (v-SRC) Autophosphorylation Site, Phosphorylated | / | Unkown | |
| HY-172470A | DSPE-PEG3400-GE11 | / | Unkown | |
| HY-155079A | (R)-DZD1516 | Control | 98.80% | Unkown |
| HY-177379 | EGFR ligand-14 | / | Unkown | |
| HY-208666 | EGFR-IN-215 | Inhibitor | / | Unkown |
| HY-163722 | EGFR/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-147995 | EGFR-IN-64 | Inhibitor | / | Unkown |
| HY-121828 | TX-1123 | Inhibitor | / | Unkown |
| HY-115952 | EGFR/HER2-IN-3 | Inhibitor | / | Unkown |
| HY-P10793 | Cyclic(YCDGFYACYMDV) | Inhibitor | / | Unkown |
| HY-178283 | EGFR-IN-177 | Inhibitor | / | Unkown |
| HY-13050A | Sapitinib fumarate | Inhibitor | / | Unkown |
| HY-145823 | EGFR-IN-42 | Inhibitor | / | Unkown |
| HY-175173 | EGFR-IN-166 | Inhibitor | / | Unkown |
| HY-139884 | EGFR-IN-18 | Inhibitor | / | Unkown |
| HY-172621 | EGFR-IN-159 | Inhibitor | / | Unkown |
| HY-179150 | EGFR-TK-IN-6 | Inhibitor | / | Unkown |
| HY-169408 | EGFR-IN-137 | Inhibitor | / | Unkown |
| HY-179031 | EGFR/VEGFR2-IN-7 | Inhibitor | / | Unkown |
| HY-157912 | EGFR-IN-102 | Inhibitor | / | Unkown |
| HY-181061 | COX/5-LO-IN-2 | Inhibitor | / | Unkown |
| HY-145867 | EGFR-IN-45 | Inhibitor | / | Unkown |
| HY-P10792A | HYNIC-H6F | Ligand | / | Unkown |
| HY-E70708 | EGFR L861Q Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-173501 | EGFR-IN-157 | Inhibitor | / | Unkown |
| HY-144605 | PROTAC EGFR degrader 3 | Inhibitor | 97.39% | Unkown |
| HY-169308 | EGFR-IN-132 | Inhibitor | / | Unkown |
| HY-158018 | EGFR-TK-IN-2 | Inhibitor | / | Unkown |
| HY-168655 | EGFR/VEGFR2-IN-3 | Inhibitor | / | Unkown |
| HY-171958 | PROTAC EGFR degrader 12 | Degrader | / | Unkown |
| HY-123891 | NS-062 | Inhibitor | / | Unkown |
| HY-162482 | EGFR kinase inhibitor 5 | Inhibitor | / | Unkown |
| HY-116277 | Z118332870 | Inhibitor | / | Unkown |
| HY-173619 | EGFR-IN-160 | Inhibitor | / | Unkown |
| HY-182073 | EGFR-IN-207 | Inhibitor | / | Unkown |
| HY-18957B | Lifirafenib maleate | Inhibitor | / | Unkown |
| HY-164489 | KU004 | Inhibitor | / | Unkown |
| HY-173500 | MG-3C | Inhibitor | / | Unkown |
| HY-180966 | Gly-PEG3-BA | Degrader | / | Unkown |
| HY-100636 | Gefitinib N-oxide | Inhibitor | / | Unkown |
| HY-181115 | EGFR-IN-193 | Inhibitor | / | Unkown |
| HY-168173 | EGFR-IN-130 | Inhibitor | / | Unkown |
| HY-RS04473 | Erbb4 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-E70699 | EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-183311 | EGFR-IN-211 | Inhibitor | / | Unkown |
| HY-180949 | EGFR-IN-189 | Inhibitor | / | Unkown |
| HY-144050 | EGFR-IN-33 | Inhibitor | / | Unkown |
| HY-129288 | GW837016X | Inhibitor | / | Unkown |
| HY-150905 | EGFR ligand-2 | Inhibitor | / | Unkown |
| HY-162300 | EGFR kinase inhibitor 4 | Inhibitor | / | Unkown |
| HY-146210 | EGFR-IN-50 | Inhibitor | / | Unkown |
| HY-164988 | TX2-120-1 | Degrader | / | Unkown |
| HY-181923 | IMP-Zn | / | Unkown | |
| HY-169216 | Multi-target kinase inhibitor 3 | Inhibitor | / | Unkown |
| HY-168433 | LSD1/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-181766 | EGFR/VEGFR2-IN-11 | Inhibitor | / | Unkown |
| HY-133453 | PROTAC EGFR degrader 1 | Degrader | / | Unkown |
| HY-178353 | EGFR/Cytokine-IN-1 | Inhibitor | / | Unkown |
| HY-115933 | EGFR/BRAF-IN-1 | Inhibitor | / | Unkown |
| HY-176938A | iAfaPhos1 | / | Unkown | |
| HY-181701 | EGFR-IN-202 | Inhibitor | / | Unkown |
| HY-147860 | EGFR-IN-61 | Inhibitor | / | Unkown |
| HY-149556 | MTX-241F | Inhibitor | / | Unkown |
| HY-109061A | Lazertinib mesylate hydrate | Inhibitor | / | Unkown |
| HY-118900 | CP-654577 | Inhibitor | / | Unkown |
| HY-175588 | EGFR-IN-170 | Inhibitor | / | Unkown |
| HY-144055 | EGFR-IN-38 | Inhibitor | / | Unkown |
| HY-161030 | EGFR-IN-92 | Inhibitor | / | Unkown |
| HY-161968 | EGFR/PI3Kα-IN-1 | Inhibitor | / | Unkown |
| HY-118175 | RG 14921 | Inhibitor | / | Unkown |
| HY-116504 | WB-308 | Inhibitor | / | Unkown |
| HY-151161 | EGFR/HER2-IN-8 | Inhibitor | / | Unkown |
| HY-175837 | EGFR-IN-172 | Inhibitor | / | Unkown |
| HY-181659 | EGFR-IN-201 | Inhibitor | / | Unkown |
| HY-W777297 | Lapatinib-13C2,15N Ditosylate | / | Unkown | |
| HY-178009 | EGFR-IN-175 | Inhibitor | / | Unkown |
| HY-178142 | Multi-kinase-IN-7 | Inhibitor | / | Unkown |
| HY-10261S1 | Afatinib-d4 | Inhibitor | / | Unkown |
| HY-161785 | EGFR-IN-117 | Inhibitor | / | Unkown |
| HY-P11890 | GPVGPS | Modulator | / | Unkown |
| HY-E70705 | EGFR G719S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-145824 | EGFR-IN-43 | Inhibitor | / | Unkown |
| HY-187517 | Anticancer agent 357 | Inhibitor | / | Unkown |
| HY-146132 | EGFR-IN-55 | Inhibitor | / | Unkown |
| HY-153557 | HER2-IN-13 | Inhibitor | / | Unkown |
| HY-P10224 | G7-18NATE | / | Unkown | |
| HY-159512 | EGFR kinase inhibitor 7 | Inhibitor | / | Unkown |
| HY-175220 | 4-TCPA | Inhibitor | / | Unkown |
| HY-168170 | EGFR/VEGFR2-IN-2 | Inhibitor | / | Unkown |
| HY-P11781 | HW12 | Control | / | Unkown |
| HY-179599 | Dyrk1A-IN-15 | Inhibitor | / | Unkown |
| HY-151158 | EGFR/HER2-IN-7 | Inhibitor | / | Unkown |
| HY-146325 | HSP90-IN-11 | Degrader | / | Unkown |
| HY-185780 | Trastuzumab-DM21 | Inhibitor | / | Unkown |
| HY-146422 | PROTAC EGFR degrader 5 | Degrader | / | Unkown |
| HY-175011 | EGFR-IN-165 | Inhibitor | / | Unkown |
| HY-N16557 | (Rac)-8-Gingerol | Inhibitor | / | Unkown |
| HY-143874 | HER2-IN-7 | Inhibitor | / | Unkown |
| HY-10261E | (R)-Afatinib | Inhibitor | / | Unkown |
| HY-153557A | HER2-IN-14 | Inhibitor | / | Unkown |
| HY-P11484 | Myosin Regulatory Light Chain MRCL3 (11-24) | / | Unkown | |
| HY-172110 | Apoptosis inducer 35 | Inhibitor | / | Unkown |
| HY-163419 | HER2-IN-18 | Inhibitor | / | Unkown |
| HY-161632 | PROTAC EGFR degrader 10 | Degrader | / | Unkown |
| HY-153605 | EGFR-IN-77 | Inhibitor | / | Unkown |
| HY-185460 | Pertuzumab-LD3 | Inhibitor | / | Unkown |
| HY-143323 | HER2-IN-9 | Inhibitor | / | Unkown |
| HY-187191 | Autophagy-IN/Ferroptosis inducer-modulator-1 | Inhibitor | / | Unkown |
| HY-163723 | EGFR-IN-116 | Inhibitor | / | Unkown |
| HY-149517 | EGFR/BRAFV600E-IN-2 | Inhibitor | / | Unkown |
| HY-151573 | EGFR/CDK2-IN-1 | Inhibitor | / | Unkown |
| HY-P10569 | Biotin HER-2 substrate peptide | / | Unkown | |
| HY-138298B | Trastuzumab deruxtecan (DAR2) | Inhibitor | / | Unkown |
| HY-146472 | EGFR-IN-52 | Inhibitor | / | Unkown |
| HY-175820 | AGW-11 | Inhibitor | / | Unkown |
| HY-E70706 | EGFR L718Q Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-170932 | EGFR/COX-2-IN-1 | Inhibitor | / | Unkown |
| HY-162964 | EGFR-IN-126 | Inhibitor | / | Unkown |
| HY-146154 | EGFR-IN-58 | Inhibitor | / | Unkown |
| HY-120412 | SKLB188 | Inhibitor | / | Unkown |
| HY-114253 | ODS-2004436 | / | Unkown | |
| HY-172179 | EGFR/VEGFR2-IN-5 | Inhibitor | / | Unkown |
| HY-162332 | EGFR-PK/JNK-2-IN-1 | Inhibitor | / | Unkown |
| HY-W174279 | Tyrphostin 8 | Inhibitor | 99.10% | Unkown |
| HY-155227S | ALK/EGFR-IN-1-d5 | Inhibitor | / | Unkown |
| HY-145844 | EGFR-IN-44 | Inhibitor | / | Unkown |
| HY-164399 | SST0116CL1 | Degrader | / | Unkown |
| HY-144676 | pan-HER-IN-1 | Inhibitor | / | Unkown |
| HY-174414 | EGFR/HER2-IN-18 | Inhibitor | / | Unkown |
| HY-100064S | O-Desmethyl gefitinib-d8 | Inhibitor | 99.84% | Unkown |
| HY-163420 | HER2-IN-16 | Inhibitor | / | Unkown |
| HY-113549 | Erbstatin | Inhibitor | / | Unkown |
| HY-110328 | PKI-166 hydrochloride | Inhibitor | / | Unkown |
| HY-RS04474 | Erbb4 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-183754 | EGFR-IN-213 | Inhibitor | / | Unkown |
| HY-163417 | HER2-IN-15 | Inhibitor | / | Unkown |
| HY-170559 | EGFR-IN-141 | Inhibitor | / | Unkown |
| HY-147797 | EGFR/HER2/CDK9-IN-2 | Inhibitor | / | Unkown |
| HY-15772G | Osimertinib (GMP) | Inhibitor | / | Unkown |
| HY-RS04210 | Egfr Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-173520 | EGFR/HDAC-IN-1 | Inhibitor | / | Unkown |
| HY-158016 | Antiproliferative agent-49 | Inhibitor | / | Unkown |
| HY-104080 | HG-5-88-01 | Inhibitor | / | Unkown |
| HY-150781 | EGFR-IN-71 | Inhibitor | / | Unkown |
| HY-173314 | EGFR-IN-155 | Inhibitor | / | Unkown |
| HY-175162 | EGFR ligand-20 | Ligand | / | Unkown |
| HY-157324 | EGFR-IN-94 | Inhibitor | / | Unkown |
| HY-144044 | EGFR-IN-30 | Inhibitor | / | Unkown |
| HY-173164 | EGFR/BRAFV600E-IN-4 | Inhibitor | / | Unkown |
| HY-183090 | EGFR/VEGFR2-IN-13 | Inhibitor | / | Unkown |
| HY-179148 | EGFR-IN-184 | Inhibitor | / | Unkown |
| HY-N6678S | (Rac)-Zearalanone-d6 | Degrader | / | Unkown |
| HY-153856A | TAS2940 fumarate | Inhibitor | / | Unkown |
| HY-146474 | EGFR-IN-54 | Inhibitor | / | Unkown |
| HY-173146 | EGFR-IN-153 | Inhibitor | / | Unkown |
| HY-168064 | EGFR-IN-124 | Inhibitor | / | Unkown |
| HY-147994 | EGFR/HER2-IN-5 | Inhibitor | / | Unkown |
| HY-E70695 | EGFR C797S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-172780 | EGFR-IN-161 | Inhibitor | / | Unkown |
| HY-157432 | EGFR-IN-97 | Inhibitor | / | Unkown |
| HY-179039 | EGFR-IN-183 | Inhibitor | / | Unkown |
| HY-120857 | BPIQ-II hydrochloride | Inhibitor | / | Unkown |
| HY-117852 | CGP-59326 | Inhibitor | / | Unkown |
| HY-164490 | LS-106 | Inhibitor | / | Unkown |
| HY-169982 | EGFR-IN-136 | Inhibitor | / | Unkown |
| HY-157526 | EGFR-TK-IN-1 | Inhibitor | / | Unkown |
| HY-12008S1 | Erlotinib-13C6 hydrochloride | Inhibitor | / | Unkown |
| HY-P11760 | HER2-targeted peptide H10 | Ligand | / | Unkown |
| HY-162062 | EGFR WT/T790M/L858R-IN-1 | Inhibitor | / | Unkown |
| HY-182742 | EGFR-IN-208 | Inhibitor | / | Unkown |
| HY-116138 | RG-14467 | Inhibitor | / | Unkown |
| HY-147826 | EGFR-IN-60 | Inhibitor | / | Unkown |
| HY-E70700 | EGFR d746-750/T790M/C797S/L858R Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-181479 | EGFR-IN-196 | Inhibitor | / | Unkown |
| HY-180823 | Topoisomerase II/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-146471 | EGFR-IN-51 | Inhibitor | / | Unkown |
| HY-161136 | EGFR/STAT3-IN-1 | Inhibitor | / | Unkown |
| HY-169428 | EGFR-IN-138 | / | Unkown | |
| HY-155200 | EGFR-IN-84 | Inhibitor | / | Unkown |
| HY-174826 | EGFR-IN-164 | Inhibitor | / | Unkown |
| HY-143729 | EGFR-IN-29 | Inhibitor | / | Unkown |
| HY-156115 | EGFR/CDK2-IN-3 | Inhibitor | / | Unkown |
| HY-144053 | EGFR-IN-36 | Inhibitor | / | Unkown |
| HY-W409652 | CLK1/4-IN-2 | Inhibitor | / | Unkown |
| HY-156457 | EGFR-IN-90 | Inhibitor | / | Unkown |
| HY-160828 | O-Desmethyl dacomitinib | Inhibitor | / | Unkown |
| HY-149632 | EGFR/HER2/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-142517 | EGFR-IN-25 | Inhibitor | / | Unkown |
| HY-162881 | DS06652923 | Inhibitor | / | Unkown |
| HY-160682 | EGFR/HER2-IN-12 | Inhibitor | / | Unkown |
| HY-161319 | EGFR-IN-104 | Inhibitor | / | Unkown |
| HY-168514 | SOS1/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-178824 | EGFR-IN-180 | Inhibitor | / | Unkown |
| HY-177989 | ER121 | Inhibitor | 98.52% | Unkown |
| HY-E70702 | EGFR d747-752/P753S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-162788 | EGFR-IN-121 | Inhibitor | / | Unkown |
| HY-170438 | EGFR-IN-139 | / | Unkown | |
| HY-149695 | EGFR-IN-91 | Inhibitor | / | Unkown |
| HY-168427 | Avitinib maleate dihydrate | Inhibitor | / | Unkown |
| HY-181099 | EGFR WT/T790M-IN-4 | Inhibitor | / | Unkown |
| HY-176279 | Hsp90-IN-42 | Inhibitor | / | Unkown |
| HY-P10994 | Eps8 peptide 327 | Inhibitor | / | Unkown |
| HY-50898S1 | Lapatinib-d7 dihydrochloride | Inhibitor | / | Unkown |
| HY-181166 | EGFR-IN-194 | Inhibitor | / | Unkown |
| HY-146136 | EGFR-IN-56 | Inhibitor | / | Unkown |
| HY-180196 | EGFR-IN-187 | Inhibitor | / | Unkown |
| HY-158175 | EGFR T790M/L858R-IN-4 | Inhibitor | / | Unkown |
| HY-10188 | SKS-927 | Inhibitor | / | Unkown |
| HY-187692 | IRAK4-IN-35 | Inhibitor | / | Unkown |
| HY-172160 | HER2-IN-21 | Inhibitor | / | Unkown |
| HY-163632 | EGFR-IN-112 | Inhibitor | / | Unkown |
| HY-P0221A | PACAP (1-38), human, ovine, rat TFA | Inducer | / | Unkown |
| HY-32721S | Neratinib-d6 | Inhibitor | / | Unkown |
| HY-153887 | HyT36(-Cl) | Control | / | Unkown |
| HY-183402 | FLLL12 | Inhibitor | / | Unkown |
| HY-110045 | ZM-306416 hydrochloride | Inhibitor | / | Unkown |
| HY-169755 | Tyrphostin 63 | Inhibitor | / | Unkown |
| HY-180325 | DDC4002 | Inhibitor | / | Unkown |
| HY-169566 | EGFR-IN-146 | Inhibitor | / | Unkown |
| HY-158829A | SSOe26 sodium scrambled negative control | / | Unkown | |
| HY-W740378 | 1,2,3,4-Tetrahydro Staurosporin | Inhibitor | / | Unkown |
| HY-118032 | Bozepinib | Inhibitor | / | Unkown |
| HY-10263 | BMS-554417 | Activator | / | Unkown |
| HY-183397 | Avitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-180480 | NSC 104999 | Ligand | / | Unkown |
| HY-135725 | D-69491 hydrochloride | Inhibitor | / | Unkown |
| HY-10325R | CL-387785 (Standard) | Inhibitor | / | Unkown |
| HY-111300 | G3130 | Degrader | / | Unkown |
| HY-180498 | NSC 57148 | Inhibitor | / | Unkown |
| HY-135727 | PF-6422899 | Inhibitor | / | Unkown |
| HY-116068 | DW532 | Inhibitor | / | Unkown |
| HY-32718S | Pelitinib-d6 | / | Unkown | |
| HY-111072 | ADS103317 | / | Unkown | |
| HY-169948 | BML-265 | Inhibitor | / | Unkown |
| HY-160068 | 2-2(t) aptamer sodium | Chemical | 99.28% | Unkown |
| HY-183456 | Tyrphostin AG17 | Inhibitor | / | Unkown |
| HY-50898S4 | Lapatinib-d7 | Inhibitor | / | Unkown |
| HY-168305 | EGFR ligand-11 | / | Unkown | |
| HY-158829 | SSOe26 sodium | / | Unkown | |
| HY-19909A | NRC-2694-A | Inhibitor | / | Unkown |
| HY-117523 | (Z)-RG-13022 | Inhibitor | / | Unkown |
| HY-N14639 | Paeciloquinone E | Inhibitor | / | Unkown |
| HY-137081 | AKOS024836912 | Inhibitor | / | Unkown |
| HY-N14635 | Paeciloquinone A | Inhibitor | / | Unkown |
| HY-16069S | Tucatinib-d6 | Inhibitor | / | Unkown |
| HY-50896S3 | Erlotinib-d8 | Inhibitor | / | Unkown |
| HY-15495B | (3S)-Tanzisertib hydrochloride | Inhibitor | / | Unkown |
| HY-N14638 | Paeciloquinone D | Inhibitor | / | Unkown |
| HY-N14637 | Paeciloquinone C | Inhibitor | / | Unkown |
| HY-163396 | EGFR-IN-107 | Inhibitor | / | Unkown |
| HY-111250 | SYR127063 | Inhibitor | / | Unkown |
| HY-183400 | BIM-46174 | Inhibitor | / | Unkown |
| HY-183377 | DMBT | Inhibitor | / | Unkown |
| HY-159047 | EGFR ligand-10 | Degrader | / | Unkown |
| HY-164527 | Si306 | Inhibitor | / | Unkown |
| HY-178740 | GI261520A | Inhibitor | / | Unkown |
| HY-158828A | SSO111 sodium scrambled negative control | / | Unkown | |
| HY-114667 | Lavendustin C6 | Inhibitor | / | Unkown |
| HY-15769A | WHI-P180 hydrochloride | Inhibitor | / | Unkown |
| HY-50896S2 | Erlotinib-d4 | Inhibitor | / | Unkown |
| HY-103443A | HKI-357 dimaleate | Inhibitor | / | Unkown |
| HY-156487 | CNBDA | Inhibitor | / | Unkown |
| HY-N14636 | Paeciloquinone B | Inhibitor | / | Unkown |
| HY-117252 | HS-72 | / | Unkown | |
| HY-50898CS | Lapatinib-d4 tosylate | Inhibitor | / | Unkown |
| HY-158828 | SSO111 sodium | / | Unkown | |
| HY-184315 | LDC8201 | Inhibitor | / | Unkown |
| HY-100742R | GNE-140 racemate (Standard) | Inhibitor | / | Unkown |
| HY-N14640 | Paeciloquinone F | Inhibitor | / | Unkown |
| HY-N20729 | Eucommin A | Modulator | / | Unkown |
| HY-169570 | EGFR-IN-149 | Inhibitor | / | Unkown |
| HY-146262 | LDC0496 | Inhibitor | / | Unkown |
| Art. -Nr. | Produktname |
Wirkung
|
Reinheit |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9907A | Trastuzumab (anti-HER2) | Inhibitor | 99.838% | Unkown |
| HY-P9S0008 | Cetuximab (PBS) | Inhibitor | 99.33% | Unkown |
| HY-P99854 | Disitamab | Inhibitor | 98.73% | Unkown |
| HY-P9912A | Pertuzumab (anti-HER2) | Inhibitor | 99.10% | Unkown |
| HY-P990947 | Tilatamig | Inhibitor | 99.99% | Unkown |
| HY-P990957 | Ficerafusp alfa | 99.71% | Unkown | |
| HY-P99866 | Duligotuzumab | Inhibitor | 99.17% | Unkown |
| HY-P99684 | Laprituximab | Inhibitor | 99.74% | Unkown |
| HY-P990238 | Anti-Human/Rat HER2 (neu) Antibody (7.16.4) | Inhibitor | 95.00% | Unkown |
| HY-P991748 | Anti-Human/Mouse Amphiregulin Antibody (AR37) | Inhibitor | 99.544% | Unkown |
| HY-P9977A | Amivantamab (FUT8-KO) | Inhibitor | 98% | Unkown |
| HY-P990755 | Pamvatamig | 95.298% | Unkown | |
| HY-P99892 | Serclutamab | 99.97% | Unkown | |
| HY-P99948 | Etevritamab | 97.00% | Unkown | |
| HY-P99324 | Tomuzotuximab | Inhibitor | ≥99.0% | Unkown |
| HY-P99715 | Losatuxizumab | Inhibitor | 99.44% | Unkown |
| HY-P99406A | Petosemtamab (FUT8-KO) | Degrader | 99% | Unkown |
| HY-P99618 | Fidasimtamab | Inhibitor | 95.00% | Unkown |
| HY-P991662 | AMG-595 Antibody | 96.94% | Unkown | |
| HY-P99558 | Timigutuzumab | Inhibitor | 97.53% | Unkown |
| HY-P990978 | Caxmotabart | 96.56% | Unkown | |
| HY-P99888 | Pimurutamab | 99.42% | Unkown | |
| HY-P990909 | Calotatug | 98% | Unkown | |
| HY-P990962 | Vislarafusp alfa | 98.98% | Unkown | |
| HY-P991159 | Ruzaltatug | Inhibitor | 95.69% | Unkown |
| HY-P990695 | Lunaxafusp (His Tag) | Inhibitor | / | Unkown |
| HY-P991780 | Anti-Mouse HER2 (domain I) Antibody (H2Mab-304) | Inhibitor | 97.589% | Unkown |
| HY-P992137 | Turigrobart | Inhibitor | 99.9% | Unkown |
| HY-P991505 | Anti-HER3 Antibody (Ab562) | Antagonist | 99.63% | Unkown |
| HY-P990972 | Azerutamig | / | Unkown | |
| HY-P991779 | Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) | Inhibitor | 99.05% | Unkown |
| HY-P992107 | Dulpatatug | Inhibitor | 99.09% | Unkown |
| HY-P991966 | Anti-Human/Mouse EGFR Antibody (7A7) | 99.45% | Unkown | |
| HY-P992140 | Varzutamig | Inhibitor | / | Unkown |
| HY-P991784 | Anti-Mouse/Human EGFR (domain III) Antibody (EMab-88) | Inhibitor | / | Unkown |
| HY-P991236 | MHES0488A | Inhibitor | / | Unkown |
| HY-P990755A | Pamvatamig (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991573 | Anti-EGFR Antibody (D2C7) | Inhibitor | / | Unkown |
| HY-P991980 | H2Mab-139 | Inhibitor | / | Unkown |
| HY-P991241 | Anti-ERBB3/HER3 (29Z6) | Inhibitor | / | Unkown |
| HY-P991967 | AVID100 Antibody | Inhibitor | / | Unkown |
| HY-P991979 | Erbicin | Inhibitor | / | Unkown |
| HY-P991783 | Anti-Mouse EGFR (domain I) Antibody (EMab-300) | Inhibitor | / | Unkown |
| HY-P992171 | ADCT-701 Antibody | / | Unkown | |
| HY-P991969 | LR004 | Inhibitor | / | Unkown |
| HY-P990408 | Anti-ERBB1/EGFR/HER1 Antibody | Inhibitor | / | Unkown |
| HY-P9968A | Nimotuzumab (powder) | Inhibitor | / | Unkown |
| HY-P991245 | Anti-ERBB3/HER3 (SGP1) | Inhibitor | / | Unkown |
| HY-P991986 | Anti-Epiregulin Antibody | Inhibitor | / | Unkown |
| HY-P990248 | Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) | Inhibitor | 98.53% | Unkown |
| HY-P991092A | IBI-334 (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P992401 | M802 | Inhibitor | / | Unkown |
| HY-P991970 | REGN3124 | Inhibitor | / | Unkown |
| HY-P991239 | NM-02 | Inhibitor | / | Unkown |
| HY-P991968 | HTI-1511 Antibody | Inhibitor | / | Unkown |
| HY-P991243 | MP-RM-1 | Inhibitor | 96.29% | Unkown |
| HY-P99295A | Imgatuzumab (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991985 | Anti-Her4 Antibody | Inhibitor | / | Unkown |
| HY-P991234 | COVA208 | Degrader | / | Unkown |
| HY-P991977 | BSI-001 | Inhibitor | / | Unkown |